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Introduction 
Prion diseases 
Formation of aberrant protein conformers plays a crucial role in several 
neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease and 
prion diseases. Though altered conformations of proteins and neuronal cell death 
are characteristic features of all neurodegenerative diseases, prion diseases are 
unique among all the other diseases in that an infectious particle is generated, 
which is devoid of nucleic acids. Prion diseases (also called “transmissible 
spongiform encephalopathies” (TSEs) are a group of neurological disorders that 
include Creutzfeldt-Jakob disease (CJD) and Kuru in humans, bovine spongiform 
encephalopathy (BSE) in cattle and scrapie in sheep and goats. In prion diseases of 
humans and mammals, the host encoded cellular prion protein (PrPC) is converted 
into a detergent-insoluble and partially proteinase K-resistant isoform, designated 
scrapie prion protein (PrPSc), which is the main component of infectious prions. 
Apart from the unconventional nature of the causative agent, prion diseases are 
peculiar in terms of their etiology; no other disease entity comprises sporadic, 
genetic and infectious variants. 
Transmissible spongiform encephalopathies in animals 
Scrapie 
Although there is a discussion that scrapie, the first known TSE was present 
before the beginning of the 18th century in northern Europe and Austro-Hungary, 
the exact origin of the disease is not clear. The earliest recorded history about 
scrapie goes back to 1755 with a discussion at the British parliament about the 
spread of a new fatal disease in sheep because it affected the quality of wool, 
Introduction	  
	  
2	  
	  
which was a highly commercial product in England at that time. Scrapie was 
documented for the first time in Germany in 1759. Clinical symptoms in sheep 
included difficulty in walking, rubbing their back against posts or trees, severe 
seizures and finally death. The only way to stop the spread of the disease was to 
isolate the infected sheep from the healthy stock and kill them. 
	  
Figure 1: First documentation of scrapie in Germany. First recorded proof of scrapie 
was described by Johann George Leopoldt in 1750, about the characteristic features and 
treatments that were used against scrapie (Source: Johann George Leopoldt (1750) 
Nuetzliche und auf die Erfahrung gegruendete Einleitung zu der Land-Wirtschaft, Part 5, 
Chapter 12 p.348. Sorau). 
There was no focused research done on scrapie until the disease was 
successfully transmitted to healthy sheep by inoculating them with the brain and 
spinal cord extracts of infected animals (Cuille & Chelle, 1938). The infective 
nature of scrapie was further strongly confirmed once immunized sheep became 
sick after injecting a vaccine prepared from the brain, spinal cord and spleen of 
scrapie infected animals (Gordon, 1946). Successful transmission of scrapie to 
laboratory mice intensified scrapie research with the aim to identify and to 
characterize the biochemical properties of the infectious agent (Chandler, 1961). 
Initially, a virus was believed to be the causative agent because of the long 
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incubation period. But scrapie agent’s resistance to heat, ultraviolet light and 
formaldehyde, which are known to destroy viral particles, suggested that a virus 
was obviously not the infectious particle. Healthy sheep injected with brain 
homogenate from scrapie infected sheep developed clinical symptoms after five 
months, whereas goats injected with the sheep scrapie brain homogenate 
developed the clinical symptoms after 23 months. The incubation time was 
shortened to eight months when the brain homogenate from scrapie infected goat 
was injected in to a healthy goat. These were the first evidences describing a 
phenomenon denoted species barrier. Even though the scrapie transmission to the 
laboratory animals was experimentally confirmed but so far there is no proof 
available for the sheep or goat scrapie transmission into humans. 
Bovine spongiform encephalopathy 
BSE affects cattle and is commonly referred to as “mad cow disease”. The 
first case of BSE was confirmed in the year 1986 in Great Britain. After this, the 
number of new cases increased significantly within the next few years in all parts 
of Great Britain, with a maximum of 36,680 cases identified in 1992. The clinical 
symptoms observed in BSE affected animals are difficulty in standing, lack of 
muscle coordination with trouble to walk and loss of weight. Affected cattle die 
within a few weeks or a few months after the onset of clinical symptoms. The 
source of BSE is still unknown, though it is believed that contaminated meat-and-
bone meal (MBM) prepared from scrapie infected sheep might be responsible for 
the spread of the disease. New BSE cases in Great Britain are declining after the 
subsequent ban of MBM by the British government.  
In the beginning of the 20th century the infectivity and disease transmission 
to heterologous animals was clearly demonstrated along with prolonged incubation 
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period. In 1996, a new type of prion disease in humans called variant Creutzfeldt-
Jakob disease (vCJD) was reported in United Kingdom (UK). The current idea is 
that vCJD is due to a transmission of BSE to humans, possibly through the 
consumption of BSE contaminated food stuffs. So far, 170 cases of vCJD have 
been recorded in Great Britain. In addition, a few vCJD cases have been reported 
outside the UK, but none so far in Germany. 
Table 1. Number of BSE reported cases worldwide until the end of 2009. 
Country > - 2006 2007 2008 2009 Total 
Austria 5 1 0 0 6 
Belgium 133 0 0 0 133 
Canada 10 3 4 1 18 
Czech republic 26 2 0 2 30 
Denmark 15 0 0 1 16 
Finland 1 0 0 0 1 
France 985 9 8 9 1011 
Germany 411 4 2 2 419 
Greece 1 0 0 0 1 
Ireland  1593 25 23 9 1650 
Israel 1 0 0 0 1 
Italy 141 2 1 1 145 
Japan  31 3 1 1 36 
Sweden 1 0 0 0 1 
Hungary 0 1 0 0 1 
Netherlands 82 2 1 0 85 
Poland  50 9 5 4   68 
Portugal 1034 14 18 8 1074 
USA 3 0 0 0 3 
Spain 681 39 25 18 763 
Switzerland  463 0 0 0 463 
United Kingdom 184,481 65 42 10 184,598 
Total 190,148 179 130 66 190,523 
 
Chronic wasting disease 
In the early 1960s, a peculiar disease called clinical wasting syndrome was 
observed in North American deer including mule deer (Odocoileus Hemionus), 
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white-tailed deer (Odocoileus Virginianus) and the Rocky Mountain elk (Cervus 
Canadensis). The histopathology of the brain tissue from the diseased animals 
showed a spongy appearance, thus the disease was recognized as a form of 
transmissible encephalopathy and renamed as chronic wasting disease (CWD) 
(Williams & Young, 1992). Research on CWD was intensified after a possible link 
between BSE and vCJD was uncovered. CWD shares certain pathophysiological 
features with scrapie and BSE. Both farming and free ranging animals can be 
experimentally infected, with incubation periods ranging from 15-36 months. 
Clinical symptoms include behavioral abnormalities, difficulty in walking, 
excessive salivation, increased drinking, urination and finally death. The disease 
can be transmitted via animal to animal contact, saliva, feces and lateral 
transmission. Even though CWD transmission was reported to animals like sheep, 
goat, deer and cattle under experimental conditions, there is no reported evidence 
of transmission of CWD to humans (Belay et al, 2004; Hamir et al, 2005; Hamir et 
al, 2006; Hamir et al, 2007; Williams & Miller, 2002). 
Prion diseases also occur in other animals such as Transmissible mink 
encephalopathy (TME) in mink (Hartsoug.Gr & Burger, 1965), Exotic ungulate 
encephalopathy (EUE) in zoo animals (Kirkwood et al, 1990) and Feline 
spongiform encephalopathy (FSE) in house and wild cats (Leggett et al, 1990). 
Transmissible spongiform encephalopathies in humans 
Prion diseases are not only restricted to animals but are also observed in 
humans. Human prion diseases can be classified into three different etiologic 
groups; sporadic, inherited and transmissible. The year, place of first occurrence 
and the etiology of the prion disease in humans are summarized in table 2. 
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Table 2. Overview of the human prion diseases. 
Name of the prion 
disease 
Place of first 
occurrence 
Reference Etiology 
Sporadic Creutzfeldt- 
Jakob Disease (sCJD) 1920, Germany 
Creutzfeldt,1920 
Jacob, 1921 Unknown 
Familial Creutzfeldt-
Jakob Disease (fCJK) 1924, Germany 
Kirschbaum 
1924 
Mutation in PrP 
gene 
Gerstmann-Straussler-
Scheinker Syndrome 
(GSS) 
1928/1936, 
Austria 
Gerstmann et al. 
1928, 1936 
Mutation in PrP 
gene 
Iatrogenic Creutzfeldt-
Jakob Disease (iCJK) 1974, USA 
Duffy et al., 
1974 
Infection by 
medical treatment 
Fatal familial insomnia 
(FFI) 1986, Italy 
Lugaresi et al., 
1986 
Mutation in PrP 
gene 
New variant Creutzfeldt-
Jakob disease (nvCJD) 
1996, Great 
Britain Will et al., 1996 Infection 
In humans, Kuru is the major acquired prion disease which was first noticed 
in the Fore tribes of Papua New Guinea in the late 1950s. Kuru means “to shake” 
in local Fore language. It is the first human form of prion disease which was 
experimentally confirmed to be infectious and transmissible. Ritual cannibalism 
practiced by the Fore tribes was touted to cause the transmission of the disease 
among the group, in which females and children were more severely affected than 
males. The disease was completely eradicated after the end of cannibalism. 
Gajdusek suggested that the disease progression occurs in three stages, in which 
the first stage includes trembling, deterioration and slurring of speech (Gajdusek, 
1973). The secondary stage (also called as “sedentary stage”) was characterized by 
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severe ataxia, shock like muscle jerks and depression while the terminal stage was 
linked to the inability of the patient to sit without an external support, defective 
muscle coordination and difficulty in eating (Gajdusek, 1973).	  
Analyzing the postmortem brain of kuru patients, Igor Klatzo noted that 
Kuru is very similar to that of another human prion disease called Creutzfeldt-
Jakob disease (CJD) (Klatzo et al, 1959). Kuru was successfully transmitted to 
chimpanzees by intracerebral injection of brain homogenate from Kuru infected 
individuals. Later, the nature of infectivity of CJD was confirmed in similar 
experiments (Gajdusek et al, 1966; Gibbs et al, 1968). 
Sporadic human prion diseases occur spontaneously with no prior family 
history and mutations in the prion protein gene (PRNP). CJD was first described 
by two German neuropathologists Hans Gerhard Creutzfeldt and Alfons Jakob 
independently (Creutzfeldt, 1920; Creutzfeldt, 1921; Jakob, 1921). CJD is 
classified into four major types, sporadic CJD (sCJD), iatrogenic CJD (iCJD), 
variant CJD (vCJD) and familial CJD (fCJD). The most common form of CJD is 
sCJD, and accounts for approximately 85% of all CJD cases (Johnson, 2005; 
Prince et al, 2006). So far, the mechanisms which trigger sCJD have not been 
identified. However, sporadic somatic cell mutations in PRNP gene, spontaneous 
refolding of prion protein or unidentified infection have been proposed to be the 
cause of sCJD but none of these have been experimentally proven (Aguzzi et al, 
2008). 
fCJD is an inherited prion disease due to mutations in the PRNP and 
accounts for about 15% of all reported cases. The age of onset is around 45 years 
and a patient may live for several years after the onset of the disease. Mutations 
include insertions, deletions or substitutions and are located especially in the 
structured C-terminal domain of PrP (Figure 2). 
Introduction	  
	  
8	  
	  
 
Figure 2: The human prion protein gene (PRNP) with all definite and suspected 
pathogenic mutations currently identified. The entire prion protein consists of residues 
23-230, with 1-22 a signal peptide for targeting to the endoplasmic reticulum and 231-253 
a signal peptide for GPI-anchor attachment. M/V and E/K219 are common 
polymorphisms that can influence the onset and phenotype of the disease (Adopted from 
Mead, 2006). 
Gerstmann–Sträussler–Scheinker syndrome (GSS) is a rare genetic 
autosomal dominant prion disease first described by Josef Gerstmann, an Austrian 
neuropathologist, along with Ernst Sträussler and Ilya Scheinker (Gerstmann et al, 
1935). Mice infected with intracerebral injection of GSS brain homogenate 
developed the disease symptoms comparable to the clinical symptoms of GSS, 
providing experimental evidence for the infectious nature of inherited prion 
diseases (Tateishi & Kitamoto, 1995). 
Fatal familial insomnia (FFI) also belongs to the group of inherited prion 
diseases with a mutation in the PRNP. So far, there are 40 families found to 
possess the mutated gene worldwide. A disease with similar symptoms was 
described in patients with no PrP mutations called sporadic fatal insomnia (SFI).  
The third group of the human prion disease is the infectious form that 
includes iCJD and the new variant Creutzfeldt-Jakob disease (nvCJD). Infectious 
forms account for less than 1% of all cases. Contaminated human growth 
hormones isolated from CJD infected individuals and contamination of surgical 
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instruments from CJD infected tissues as a result of medical procedure accounted 
for the iatrogenic forms (Bernoulli et al, 1977; Davanipour et al, 1984; Duffy et al, 
1974; Kondo & Kuroiwa, 1982). vCJD develops probably due to the intake of BSE 
contaminated food products and in contrast to the classical form has a very long 
incubation period (Aguzzi & Weissmann, 1996; Bruce et al, 1997; Collinge et al, 
1996; Hill et al, 1997). So far, 280 vCJD cases have been confirmed worldwide 
since the first cases reported in 1996. The number of cases may rise in the future 
considering the unusually prolonged incubation periods of this disease. There is 
evidence that vCJD in contrast to sCJD, can be transmitted through blood products 
(Aguzzi & Glatzel, 2004; Llewelyn et al, 2004; Peden et al, 2004; Wroe et al, 
2006). This indicates that prion contaminated blood products can significantly 
increase the risk of prion disease in humans. As a consequence people who lived in 
the UK between 1980 and 1996 were not allowed to donate blood in countries 
outside the UK. 
Clinical signs and neuropathology of human prion diseases 
The main characteristic features of all human prion diseases are prolonged 
incubation periods with complex etiology and differences in their disease duration, 
onset of clinical manifestation and neuropathology. Onset of the symptoms in 
sCJD is approximately around the age of 60 years. In fCJD and GSS, the 
symptoms are observed at an average age of 45-50 years, whereas in vCJD clinical 
signs are detected in relatively younger patients with an average age of 29 years. 
Kuru occurs at a wide range of ages between 4-60 years which is possibly 
associated with the concentration and the exposure time of the infectious particle. 
Prion diseases not only differ in their incubation periods but also in the duration 
between the onset of clinical signs and death. The average duration between the 
onset of the clinical symptoms and death in sCJD is only 2-3 months while in 
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vCJD the average is 14 months and that of Kuru is 12 months. GSS shows an 
exceptionally long duration of the disease with an average of 5 years (Collinge, 
2001; Johnson & Gibbs, 1998).  
 
Figure 3: Neuropathological features of transmissible spongiform encephalopathies. 
Characteristic histological and immunohistochemical features between the brain samples 
of a control (upper row) and from Creutzfeldt–Jakob disease (CJD; lower row) patients. 
Brain samples were stained with hematoxylin and eosin (H&E), immunohistochemical 
staining with anti-GFAP antibody (GFAP) and an anti-prion antibody (PrP). Brain 
spongiform and neuronal cell death are observed by H&E staining. Astrogliosis and prion 
deposits are demonstrable using GFAP and PrP immunostains of CJD brain samples 
(Adopted from Aguzzi et al, 2001). 
Clinical symptoms also differ among the human forms of prion diseases. 
Kuru is primarily characterized by tremor, swallowing difficulty, ataxia, and 
muscle in-coordination. CJD is primarily characterized by dementia, lack of 
muscle coordination and behavioral changes. The symptoms of FFI are phobias, 
paranoia, inability to sleep followed by the loss of weight and disruption of the 
autonomic nervous system. In common, cerebellar ataxia, slurred speech or visual 
impairment and unsteadiness with difficulty in walking are observed at the 
beginning whereas severe ataxia and dementia are observed in later stages of the 
disease (Wadsworth & Collinge, 2007).  
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In prion disease, neuropathological changes which include brain 
vacuolation, astrogliosis and accumulation of PrP amyloid deposits of various 
structure and size are observed (Figure 3). Kuru amyloid plaques were named after 
they were found in the brain of Kuru patients and are homogeneous deposits of 
protein aggregates (Klatzo et al, 1959). In addition, multicentric plaques were 
observed in postmortem brain of GSS patients and characteristic spiked-ball 
plaques were observed in vCJD patients (Brown, 1992); (Will et al, 1996). 
Prion protein 
Nature of the infectious agent 
Although scrapie is known for more than 250 years and other prion diseases 
are known for several decades now, the cause of the infectious agent responsible 
for TSEs is still a mystery. Experiments to understand the biophysical and 
chemical properties are limited by difficult, time consuming and expensive 
bioassays. All the assays were performed in sheep and goats until successive 
transmission of scrapie to laboratory mice was discovered (Chandler, 1961). 
Scrapie was suggested to be caused by a slow virus, since healthy animals 
developed clinical signs after the intracerebral inoculation of brain homogenate 
contaminated with scrapie agent. However, the scrapie agent was found to be 
highly resistant towards formalin treatment that efficiently inactivates viral 
particles (Gordon, 1946). The observation that animals developed the disease after 
the inoculation of formalin treated scrapie brain suspension, laid a strong base for 
the speculation of a slow non-viral infection (Sigurdsson, 1954). The scrapie agent 
was also resistant to ultraviolet radiation, which causes damage to nucleic acids, 
suggesting that the infectious material was largely composed of protein rather than 
DNA/RNA (Alper et al, 1967; Griffith, 1967). In control experiments, however, 
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scrapie infectivity was diminished upon treatment with proteinase K, diethyl 
pyrocarbonate, SDS, guanidinium thiocyanate, phenol and urea, suggesting that 
scrapie agent is composed of proteins required for infectivity (Prusiner et al, 1981). 
The term “Prion” (meaning proteinaceous infectious particles) was coined by 
Stanley B Prusiner in order to differentiate scrapie infectious particles from viruses 
or viroids (Prusiner, 1982). In 1982, Prusiner and colleagues reported a protein that 
co-purified with scrapie infectivity (Bolton, 1982).The protease resistant protein 
obtained from proteinase-K-treated Syrian hamster (SHa) brain suspension had a 
molecular weight of 27-30kD and was designated as scrapie prion protein 27-30 
(PrP27-30), and was glycosylated (Bolton et al, 1985; Prusiner et al, 1983).  
The subsequent determination of the amino acid sequence at the N-terminus 
of PrP27-30 allowed molecular cloning of the prion protein (PrP) gene. 
Interestingly, PrP is expressed by the host and no significant alteration in PrP 
mRNA level was found between healthy and infected animals (Oesch et al, 1985). 
The disease associated protease resistant form of PrP was designated as scrapie 
prion protein (PrPSc) while the normal protease sensitive cellular prion protein was 
designated as PrPC. PrPSc is found in all forms of prion diseases and is absent in 
other neurodegenerative disease such as Alzheimer’s disease, Parkinson’s disease 
and amyotrophic lateral sclerosis (Bockman et al, 1985; Bockman et al, 1987; 
Brown et al, 1986; Manuelidis, 1985; Manuelidis et al, 1985). The expression level 
of glial fibrillary acidic protein (GFAP) is elevated in prion infected mice in 
parallel with PrPSc accumulation. However, mice devoid of GFAP did not show 
any alteration in disease progression (Gomi et al, 1995; Manuelidis et al, 1987; 
Tatzelt et al, 1996). 
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Many attempts to disprove the prion hypothesis and to demonstrate that 
viral particles are the pathogen have failed; however, the definite molecular 
composition of the infectious agent is still unknown. Host encoded 25-mer 
polynucleotides were co-purified with the infectious particles, which were later 
identified as non-essential components of the infectious units (Safar et al, 2005). 
Purified disease associated infectious molecules are not only composed of PrPSc 
but also contain significant amounts of lipids and carbohydrates (Appel et al, 1999; 
Dumpitak et al, 2005; Klein et al, 1998). Recent findings described that infectious 
prion particles can be generated from bacterially expressed recombinant prion 
protein (rPrP) which also cause prion diseases in mice (Kim et al, 2010; Legname 
et al, 2004; Wang et al, 2010). This result strongly supports the protein only 
hypothesis. 
Conformational transition from PrPC to PrPSc  
Although PrPC and PrPSc have the same amino acid (aa) sequence (primary 
structure) and posttranslational modification, PrPSc differs from PrPC by its 
biochemical and biophysical properties such as solubility and secondary structure. 
This difference in secondary structure indicates that PrPSc must be an altered 
conformer of PrPC. The conformational transition of PrPC to PrPSc is believed to 
take place at the cell surface or in endosomes (Borchelt et al, 1992; Caughey & 
Raymond, 1991). The exact mechanism for the conformational change is not 
known but several theories have been proposed. The heterodimer model assumes 
that PrPSc interacts with PrPC, thereby catalyzing its conversion to PrPSc (Figure 4) 
(Cohen et al, 1994). 
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Figure 4: Heterodimer model for prion replication. Infectious prions are formed 
through autocatalytic process by direct interaction between PrPC-PrPSc. Multiple PrPSc 
molecules are formed, stabilized and form elongated prion fibrils. Later fibrils are broken 
in to smaller unit that act as a seed for further PrPSc conversion (Adopted from Shorter & 
Lindquist, 2005). 
In contrast, the nucleation dependent polymerization mechanism postulates 
that the nuclear core composed of PrPSc molecules act as a seed and catalyze the 
formation of PrPSc. This process continues until the formation of larger aggregates 
which act as a reservoir for PrPSc seeds (Jarrett & Lansbury, 1993). PrPSc 
replication in vivo takes place from some months to several years depending on the 
expression of PrPC by the host. Interestingly, proteinase-K resistant and infectious 
PrPSc can be produced through an in vitro method called protein misfolding cyclic 
amplification (PMCA) (Soto et al, 2002). Propagation of PrPSc was achieved by 
the addition of PrPSc seeds to the hamster brain homogenate containing PrPC in a 
test tube. PrPSc generated by PMCA method is infectious (Bieschke et al, 2004; 
Kim et al, 2010; Wang et al, 2010; Weber et al, 2007). Expression of PrPC by the 
host is required for the replication of infectious prion (Bueler et al, 1992). 
Interestingly, the N-terminal domain (aa 23-90) and the C-terminal 
glycosylphosphatidylinositol (GPI) anchor are dispensable for the generation of 
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infectious prions (Chesebro et al, 2005b; Fischer et al, 1996). Nucleic acids and 
lipids have been shown to be involved in conversion and propagation of prions 
from bacterially expressed recombinant PrP (Wang et al, 2010). But a different 
study revealed that infectious prions can be generated from recombinant PrP 
without any cofactors by PMCA technique (Kim et al, 2010). 
Prion protein gene 
In humans, chromosome number 20 possesses the PrP (PRNP) gene while 
in mice it is located on chromosome number 2. The PrP gene in humans and mice 
has 3 exons with the complete open reading frame (ORF) formed within the 3rd 
exon. The human prion protein is composed of 253 amino acids. The mouse and 
human prion protein genes were cloned in 1986 (Basler et al, 1986; Kretzschmar et 
al, 1986; Locht et al, 1986; Oesch et al, 1985; Sparkes et al, 1986). PrP is 
expressed ubiquitously in the embryonic stage (Kretzschmar et al, 1986), whereas 
in adults high level of expression is found in central nervous system (CNS) and to 
a lesser extent in spleen lymphocytes (Bendheim et al, 1992; Bueler et al, 1992). 
Lower PrP expression levels are also observed in muscle and lymphoid tissues 
(Bendheim et al, 1992). 
 
 
Figure 5: Schematic diagram of human PrP gene. PRNP gene located on chromosome 
number 20 and it has three exons with the entire ORF lying in the 3rd exon. 
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Biogenesis and structure of PrP 
PrP biogenesis starts with the translocation of the nascent PrP amino acid 
chain into the lumen of the endoplasmic reticulum (ER). In the ER lumen, a series 
of posttranslational modifications takes place such as cleaving of the N-terminal 
signal sequence (aa 1-23), addition of glycans (aa 181 and 197), addition of GPI 
anchor to the C-terminal end after cleaving the GPI signaling sequence (aa 231-
253) and formation of disulfide bond between aa 170 and 214. During trafficking 
through the secretory pathway the core glycans are processed into complex 
structure. Finally, mature PrP is transported to the outer leaflet of the plasma 
membrane. At the cell surface, PrP is present in three forms; unglycosylated, 
monoglycosylated and diglycosylated (Prusiner, 1989; Weissmann, 1994). 
Structural studies with recombinantly expressed PrP (rPrP) revealed a large 
flexible disordered N-terminal region, containing an octa-repeat region, and a 
structured C-terminal domain (aa 126-226). This autonomously folding domain 
contains three α-helical regions (aa 144-154, aa 175-193 and aa 200-219) and a 
short two-stranded β-sheet (aa 128-131 and aa 161-164) (Donne et al, 1997; Riek 
et al, 1996; Riek et al, 1997). The C-terminal domain is characterized by extensive 
co- and posttranslational modifications, including two N-linked glycans with 
complex structure, a disulfide bridge and a C-terminal GPI anchor (rev. in (Tatzelt 
& Winklhofer, 2004). Interestingly rPrP from different species including frog, 
turtle and chicken show identical structural features with mammalian PrP, 
indicating that the physiological function of PrP is evolutionally conserved 
(Calzolai et al, 2005)  
PrPSc is different from PrPC with respect to its biochemical properties such 
as resistance to proteolytic digestion, formation of fibrillar structures and  
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Figure 6: Three dimensional structure of recombinant Syrian hamster prion 
protein. Highly structured C-terminal domain showing with three α-helices (red and 
yellow) and two anti-parallel β-strands (blue) along with flexible N-terminal region (gray) 
(Adopted from Burns et al, 2003). 
fluorescence birefringence in the presence of Congo red (Prusiner et al, 1983). 
Nuclear magnetic resonance (NMR) or X-ray crystallographic data on the structure 
of PrPSc are not available because of the insoluble character of PrPSc. Experiments 
with circular dichorism (CD) and infrared spectroscopes provided the first clue 
about the structure of PrPSc (Pan et al, 1993). PrPC is mainly composed of α-helices 
(42%) with some β-sheets (3%), whereas PrPSc contains less α-helical (30%) 
domains and high β-sheet (43%) structure (Sakaguchi, 2007). A study using 
negative stain electron microscopy with 2D crystalline like arrays prepared from 
purified scrapie material suggested that PrPSc may be composed of parallel β-helix 
rather than β-sheet since both β-sheet and β-helix cannot be differentiated by 
spectroscopic methods (Wille et al, 2002). Structural data from brain derived PrPSc 
by mass spectrometry analysis of hydrogen-deuterium exchange also suggesting 
the presence of β-helix at the C-terminal region PrPSc (Smirnovas et al, 2011). 
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Function of prion protein 
As mentioned above, PrPC is expressed in all tetrapods and birds and the 
structural properties are highly conserved. Therefore, it is plausible to assume that 
the physiological function of PrPC is also conserved. During the last three decades, 
a number of studies have been carried out to uncover the functional properties of 
PrPC. However, the function of PrPC is still enigmatic. Approaches to unmask the 
cellular function of PrPC by several groups are discussed in detail below.  
Studies from PrP knockout mice   
Mice with a targeted disruption in the PrP gene (Prnp) do not show any 
distinct phenotype (Bueler et al, 1992). However, PrPC expression is indispensable 
for the replication of scrapie prions; mice devoid of PrPC are resistant to prion 
diseases and do not propagate infectious prions (Bueler et al, 1993; Bueler et al, 
1992; Rambold et al, 2008a). Subsequent studies on PrP knockout mice exhibited 
slight phenotypic alterations, such as changes in circadian cycle rhythms (Tobler et 
al, 1996), olfaction (Le Pichon et al, 2009), abnormalities in neuronal excitability 
(Collinge et al, 1994), altered neurite outgrowth (Santuccione et al, 2005) and 
deficiency in proliferation of hematopoietic stem cells and neural precursor cells 
(Steele et al, 2006; Zhang et al, 2006). Upon using a stroke model, it became more 
clear that PrP knockout mice are highly sensitive to ischemic insult, hypoxia and 
seizures (McLennan et al, 2004; Mitteregger et al, 2007; Shyu et al, 2005; Spudich 
et al, 2005; Weise et al, 2006). Based on the above results, many functional roles 
have been attributed to PrPC such as changes in synaptic transmission and neuronal 
excitability, protection against oxidative stress and a role in cell proliferation, 
differentiation and adhesion (rev. in (Linden et al, 2008; Nicolas et al, 2009).  
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Since PrP null mice do not show any significant phenotype, PrPC does not 
seem to be an essential protein, at least under optimal conditions in a laboratory. 
However, alternatively compensatory mechanisms might have been activated in 
PrPo/o mice that overcame the loss of PrPC. To identify if prion knockout mice 
develop any compensating mechanism during embryogenesis to balance the lack 
of PrPC, Mallucci et al, generated a PrP conditional knockout mice, in which PrP 
expression is turned off during postnatal stage. However, the conditional knockout 
mice did not have any phenotype either (Mallucci et al, 2002). Thus, although 
PrP0/0 mice have been available for more than 2 decades the definite physiological 
function of PrPC is still enigmatic. 
Stress-protective functions of PrPC 
The first line of evidence indicating a stress-protective function of PrPC 
arose from experiments with hippocampal neurons isolated from the PrP knockout 
mice (Amitsuka et al, 1999). Later, it was found that PrP knockout mice are 
sensitive to ischemic brain damage, kainate induced seizure and to oxidative stress 
(Rangel et al, 2007). PrPC knockout mice subjected to an ischemic brain injury 
show larger infarct volume with an increased activity of caspase-3 and expression 
of PrPC rescues the brain injury from the ischemic insults and improves the 
neurological performance (Mitteregger et al, 2007; Spudich et al, 2005). In 
addition, up regulation of PrPC mRNA and high immune reactivity of PrPC is 
observed during an ischemic condition in humans and rodents (McLennan et al, 
2004). In a cell culture model, recently established in our group, expression of 
cellular PrPC protects human neuroblastoma (SH-SY5Y) cells from stress-induced 
apoptosis (Rambold et al, 2008a). Based on these findings, it appears that PrPC 
may be involved in stress-protective and cell survival signaling pathways 
(Resenberger et al, 2011). 
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PrP protection against PrP∆HD 
In an experiment to analyze PrPC regions responsible for the conversion of 
PrPSc, it emerged that the deletion of the internal hydrophobic domain (HD) (aa 
112-128) resulted in the generation of a neurotoxic mutant PrP, denoted as PrP 
∆HD or PrP∆CR (Baumann et al, 2007; Li et al, 2007a; Shmerling et al, 1998). 
Interestingly removal of 20 amino acids within the HD is enough to cause 
formation of neurotoxic molecule (Li et al, 2007a). Transgenic mice expressing 
PrP∆HD develop severe ataxia and neurodegeneration in the cerebellum and die 
100 days after birth. Surprisingly, this neurodegenerative phenotype was 
completely abolished by the co-expression of a single copy of PrPC (Baumann et 
al, 2007; Li et al, 2007a; Shmerling et al, 1998). PrP∆HD-induced apoptotic cell 
death and protective function of wtPrP upon co-expression have been 
demonstrated also in cultured cells (Rambold et al, 2008b). In a different cell 
culture model expression of  PrP∆105-125 was shown to induce cation-permeable 
channels or membrane pore dependent current which was inhibited by over 
expression of PrP or by the addition of glycosaminoglycan (Solomon et al, 2010). 
Biochemical properties of PrP∆HD mutants indicate that the neurotoxic function 
resulted from the alteration in the normal function of PrP (Ballif et al, 2007; 
Christensen & Harris, 2009). 
Role of PrP in copper binding and oxidative stress 
Several in vitro and in vivo studies indicate that the histidine residues 
located within the octa-repeat region of the N-terminus of PrPC are associated with 
Cu2+ binding activity (Brown et al, 1997b; Stockel et al, 1998; Viles et al, 1999). 
Reduced levels of Cu2+ were observed in the subcellular and synaptosomal 
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fractions prepared from brain of PrP knockout mice (Brown et al, 1997a). 
However, alterations in brain Cu2+ level in PrP0/0 mice were challenged by 
Waggoner et al., (Waggoner et al, 2000). Further studies showed that binding of 
Cu2+ to PrP induces the formation of a misfolded PrP conformer distinct from 
PrPSc and that it stimulates endocytic trafficking of PrP (Pauly & Harris, 1998; 
Perera & Hooper, 2001; Quaglio et al, 2001). Since PrPC is largely localized in the 
presynaptic membrane, so PrPC might have an influence on synaptic Cu2+ 
homeostasis. In conclusion, the findings summarized above could suggest that 
PrPC might be involved in modulating the Cu2+ dependent intracellular signaling 
cascade directly or indirectly in the presynaptic cleft.  
For many years, oxidative stress has been linked to neuronal cell death in 
neurodegenerative diseases. An increase in oxidative stress biomarkers was 
described in PrP0/0 mice, indicating that PrPC might be involved in the suppression 
of oxidative stress (Wong et al, 2001). Decreased super oxide dismutase-1 (SOD-
1) activity was identified in neuronal cells from PrP null mice (Brown et al, 
1997b). SOD-1 requires cofactors such as Cu2+ and Zn2+ for its cellular function 
and hence the impaired Cu2+ levels in PrP null neurons could be responsible for the 
decreased SOD-1 activity that sensitize the cells to increased oxidative stress. PrP 
itself possess a SOD-like enzymatic activity that is abolished in mutants lacking 
the octa-repeat region, which is involved in Cu2+ binding (Brown et al, 1999).  
Neurotoxic signaling through PrPC 
Prion propagation and neurotoxicity are the two central events in prion 
disease and the expression of PrPC is essential for both. Brandner and colleagues 
were the first to show an important role of PrPC as a mediator of PrPSc-induced 
neurotoxicity in prion disease. They grafted PrPC over expressing neural tissue into 
Introduction	  
	  
22	  
	  
the brain of PrP0/0 mice. After the intracerebral inoculation with scrapie prions the 
grafted PrPC expressing brain tissue propagated PrPSc and developed clinical 
characteristic features of prion disease, but the neighboring tissue devoid of PrPC 
stayed healthy although PrPSc  spread from graft to the host brain (Brandner et al, 
1996). The role of PrPC as a mediator of PrPSc-induced neurotoxicity was further 
supported by other transgenic mouse models, scrapie-infected mice expressing 
non-neuronal PrPC did not develop clinical symptoms, although they accumulate 
PrPSc in addition with astrogliosis (Mallucci et al, 2003). Similarly, transgenic 
mice expressing anchorless PrP and infected with PrPSc do not develop clinical 
disease though they propagate infectious prions (Chesebro et al, 2005b). 
Cell culture experiments from our group support the idea that the 
expression of PrPC is required to transmit neurotoxic signals linked to PrPSc. 
Furthermore, the intrinsically disordered N-terminal domain and GPI anchor are 
required for this activity (Rambold et al, 2008b; Resenberger et al, 2011). The in 
vivo and in vitro studies described above support the scenario that PrPSc mediates 
its toxic effects through an interaction with PrPC. This PrPC/PrPSc complex could 
possibly modulate PrPC dependant signaling pathways (Resenberger et al, 2011).  
Putative co-receptors for PrP 
PrPC attachment via GPI moiety to the detergent resistant microdomains 
(DRMs) of plasma membrane would suggests that PrPC might be involved in 
signal transduction, since DMRs are widely recognized as membrane signaling 
platforms (Allen et al, 2007; Haigh et al, 2009). Antibody mediated PrP cross-
linking activates Fyn tyrosine kinase and as a consequence phosphorylation of 
extracellular signal-regulated kinase 1/2 (ERK1/2) in a caveolin-1 dependent 
manner (Mouillet-Richard et al, 2000; Schneider et al, 2003; Toni et al, 2006). 
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Establishment of synaptic like structure in cultured primary hippocampal neurons 
was observed after the addition of rPrP, however, this effect was blocked by 
protein kinase C and SRC kinase inhibitors (Kanaani et al, 2005). Binding of Cu2+ 
to PrPC activates phosphatidylinositol 3-kinase (PI3K), thereby triggering the 
neuroprotective signals (Vassallo et al, 2005). A recent study shows that increased 
levels of phosphorylated mitogen-activated protein kinases (MAPKs) are involved 
in neuro protection against PrPSc induced toxicity (Uppington & Brown, 2008). 
 In order to transmit intracellular signals, PrPC would require a co-receptor 
since it does not have any direct contact to the cytosol. Several biological 
molecules are proposed to interact with PrP and are discussed in detail below. So 
far, 37/67 kDa laminin receptor (Gauczynski et al, 2001; Rieger et al, 1997), an 
unknown 66 kDa membrane protein (Martins et al, 1997) and the stress-inducible 
transmembrane protein 1 (STI1) are proposed as interacting partners of PrPC 
(Zanata et al, 2002). It has been shown that amino acid residues 230-245 from 
STI1 interact with the hydrophobic region (aa113-128) of PrP through which PrP 
transduces the neuroprotective signals (Zanata et al, 2002). A recent study reported 
that the recruitment of PrPC-STI1complex at the cell surface induces the 
neuroprotection and neuritogenesis, with increased protein synthesis via PI3K-
mTOR signaling and this neuroprotective translational stimulation is abolished in 
scrapie infected cells (Roffe et al, 2010). 
Using yeast two-hybrid technology, Rieger and colleagues demonstrated 
that a 37 kDa laminin receptor precursor (LRP) interacts with PrPC, thereby acting 
as a cellular receptor or co-receptor for PrPC (Rieger et al, 1997). The 37 kDa 
LRP/67 kDa LR and PrPC are co-localized at the cell surface of neuronal and non-
neuronal cells (Gauczynski et al, 2001). PrPC has two different sites for LRP/LR 
binding; the direct binding domain at C-terminal region (aa 144-179) and the 
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indirect binding domain at N-terminal region (aa 53-93). Similar to that, LRP/LR 
aa regions 161-179 involved in direct and indirect interaction with PrPC via amino 
acids 180-285. 
Additional PrP interacting proteins 
Proteins associated with intracellular vesicles or caveolae-like domains such 
as synapsin, growth factor receptor-bound protein 2 (Grb-2), prion interactor 1 
(Pint1), p75, caveolin and casein kinase 2 (CK2) were also described to form 
complexes with PrPC (Della-Bianca et al, 2001; Meggio et al, 2000; Mouillet-
Richard et al, 2000; Spielhaupter & Schatzl, 2001).  Interestingly, PrPC associated 
with caveolin or CK2 induces intracellular signaling through Fyn kinase or 
phosphotransferase activity of CK2α respectively (Meggio et al, 2000; Mouillet-
Richard et al, 2000). Abnormally folded PrP Q217R, a mutant associated with 
GSS, was shown to bind to Bip (heat shock 70 kDa protein 5(HSP70). As a 
consequence PrP Q217R was retained in the endoplasmic reticulum. Further, Bip-
PrPQ217R enhanced the proteasomal degradation of abnormally folded mutant 
PrP, thus preventing the formation of protein aggregates, suggesting that Bip might 
play a significant quality control role in PrP biogenesis (Jin et al, 2000). GFAP and 
Bcl2 were also found to interact with PrP (Kurschner & Morgan, 1995; Oesch et 
al, 1990). Cytosolic prion protein co-aggregates with Bcl2 and thereby triggers 
apoptotic cell death. This toxicity is abolished by the co-expression of cytosolic 
heat shock proteins (Rambold et al, 2006). 
The function of glutamate receptors was also proposed to be modulated by 
PrPC, but evidences are inconsistent. Electrophysiological findings suggest that 
PrPC binds to the NR2D subunit of the N-Methyl-D-aspartic acid receptor 
(NMDAR) complex and there by suppresses the NMDAR complex activity 
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(Khosravani et al, 2008). Recent study shows PrPC-laminin γ1 complexes along 
with group I metabotropic glutamate receptors (mGluR1/5) and initiates signaling 
cascade for neurite outgrowth (Beraldo et al, 2011). More biochemical evidences 
are needed to establish the functional link between NMDAR and PrPC. Apart from 
these, PrPC is proposed to be a cellular receptor for amyloid-β (Aβ) oligomers. 
Binding of Aβ oligomers with PrPC initiates synaptic dysfunction and altered long-
term potentiation (LTP) in hippocampal neurons (Lauren et al, 2009). This was 
challenged by Kessels et al., in a study, where Aβ oligomers induced synaptic 
dysfunction, loss of dendritic spines and altered LTP were irrespective of PrPC 
expression (Kessels et al, 2010). At the same time, independent studies by 
different groups supported the hypothesis that PrPC might be a receptor for Aβ 
oligomer (Barry et al, 2011; Caetano et al, 2011; Chung et al, 2010; Freir et al, 
2011; Resenberger et al, 2011). Recently, our group identified that PrPC not only 
can mediate toxic signals induced by Aβ oligomers, but also can transmit deadly 
signals by different β-sheet rich oligomeric conformers (Resenberger et al, 2011). 
 
Figure 7: Schematic representations of the binding domains of PrPC ligands on 
human PrPC molecule. Human PrPC molecule contains a ER-SS: endoplasmic reticulum 
signal sequence, OR: octa-repeat region, HD: hydrophobic domain, α: α-helical region, 
GPI-SS: glycosylphosphatidylinositol anchor signal sequence. Lines are indicating the 
binding site for each PrPC binding molecule, which is also represented by amino acid 
numbers in parentheses (Adopted from Lee et al, 2003).  
Introduction	  
	  
26	  
	  
Different domains of PrPC are engaged in binding with a variety of proteins 
favoring the macromolecular complex theory. Even though several proteins are 
considered to be associated with PrPC at the cell surface, in cytosol, in endocytic 
compartments and in the secretory pathway, the role of PrP binding protein and the 
complete signaling cascades are still elusive. Identifying the cellular receptor for 
PrPC and its function would have a beneficial role in designing therapeutic 
strategies in prion disease. 
Table 3. Proposed cellular receptors for PrP and its subcellular binding sites. 
PrPC interacting 
molecules Subcellular binding sites 
Bcl-2 unknown (Kurschner and Morgan, 1995) 
Hsp60 unknown (Edenhofer et al., 1996) 
Nrf2 unknown (Yehiely et al., 1997) 
Aplp1 cell surface (Yehiely et al., 1997) 
Caveolin-1 caveolae raft (Mouillet-Richard et al., 2000) 
Laminin cell surface (Graner et al., 2000) 
CK2 caveolae raft (Meggio et al., 2000) 
N-CAM caveolae-like domain (Schmitt-Ulms et al., 2001) 
Synapsin 1b intracellular vesicles (Spielhaupter and Schätzl, 2001) 
p75 caveolae raft (Della-Bianca et al., 2001) 
Grb2 intracellular vesicles (Spielhaupter and Schätzl, 2001)  
Laminin receptor cell surface (Gauczynski et al., 2001b) 
Pint 1 unknown (Spielhaupter and Schätzl, 2001) 
STI 1 cell surface (Zanata et al., 2002) 
GAG cell surface (Pan et al., 2002) 
NRAGE cytosol (Bragason and Palsdottir, 2005) 
NR2D(NMDAR) cell surface (Khosravani et al, 2008)  
Shadoo 
Sprn gene and its polymorphisms 
In search for homologs of PrPC, a new gene termed Sprn (“shadow” of the 
prion protein) that is highly conserved from fish to mammals was identified. 
Expression of Sprn gene in all mammals suggests that Shadoo (Sho) might have an 
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important physiological function. A SPRN pseudogene was described in humans 
and primates and may have arisen due to the segmental duplication (Harrison et al, 
2010; Premzl et al, 2004). A human SPRN pseudogene has an overlap with the 
non-coding exon of SYCE1 gene that is involved in meiosis in mammals (Harrison 
et al, 2010). Chromosomal rearrangements in fish have produced multiple paralogs 
of Sprn gene and at least 2 Sprn gene copies are present in fish genome (Harrison 
et al, 2010; Premzl et al, 2004; Premzl et al, 2003; Strumbo et al, 2001; Strumbo et 
al, 2006). 
 
 
Figure 8: Schematic diagram of human SPRN gene. SPRN gene has two exons and the 
entire ORF of human SPRN gene is located within the second exon. E1, exon 1; E2, exon 
2; ORF, open reading frame. 
A study in humans revealed allelic variations in SPRN gene. A common A 
to G change at the 11th position downstream from the start codon, amino acid 
change T7M within the N-terminal signal peptide and silent polymorphism at 
codon 61 were identified in human SPRN gene (Beck et al, 2008; Daude et al, 
2009a; Daude et al, 2009b). Many polymorphisms have been identified in sheep. A 
common silent polymorphism at Y112Y and allelic variation at V71A were 
observed. Surprisingly, several allelic variations within the internal HD were also 
identified (Daude et al, 2009). The mouse genome was also analyzed, but genetic 
variations in mouse Sprn gene have not been identified as yet. 
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Table 4. Polymorphisms in SPRN gene (Adopted from Daude et al, 2009). 
Position -11 T7M G61G 
Genotype (%)  A/A     37.6 T/T     45.2 C/C     49.4 
 G/G     15.1 C/T     39.8 C/T     43 
 A/G     47.3 C/C     15.1 T/T     7.5 
Predominant allele A = 61.7% T = 65.1% C = 71.0% 
Expression of Sprn gene 
Sho expression in mice and sheep is restricted to the CNS especially to the 
hippocampus, cerebellum and to a lesser extent to the cerebral cortex, thalamus 
and medulla (Lampo et al, 2010; Watts et al, 2007). The immunohistochemistry 
and in situ hybridization analysis suggested that Sho might be primarily distributed 
at synapses (Lampo et al, 2010) and it may have an overlapping expression with 
PrP in certain regions of the brain (Watts et al, 2007). Prompted by these 
experimental data, expression patterns of Sprn mRNA and protein level were 
examined in prion infected mice. In one study it was shown Sho protein level was 
drastically reduced upon prion infection, whereas mRNA level was unaltered or a 
little elevated (Lloyd et al, 2009; Watts et al, 2007). Sho degradation in parallel 
with prion infection might be coupled with a proteostatic effect (Westaway et al, 
2011) and during disease progression Sho might be degraded by cellular 
compartments such as proteaosome or lysosome. A different study illustrated that 
Sho reduction in prion diseased mice is not a general feature and might depend on 
the prion strain (Miyazawa & Manuelidis, 2010). Furthermore, transgenic mice 
over expressing Sho infected with scrapie prions developed the clinical disease 
similar to that of wild type mice. Thus, it is not likely that Sho expression has an 
effect on the pathogenesis of prion disease (Wang et al, 2011). 
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Structure of Sho 
Sho is a neuronal glycoprotein, having positively charged N-terminal 
BR/RG repeats, a central HD and a glycosylation site at the C-terminal region and 
is attached to the plasma membrane through a GPI anchor. Notably, there is 
significant sequence homology of the HD of PrP and Sho. So far, no experimental 
evidence is available to state that the N-terminal region of Sho binds to copper. 
However, it contains a RGG box that is associated with RNA binding. CD 
spectroscopic analysis of recombinant mouse Sho (mSho) suggests that it might be 
completely unstructured (Watts et al, 2007).  
 
Figure 9: Schematic presentation of the similarities in hydrophibic domains between 
PrP and Sho. ER-SS: endoplasmic reticulum signal sequence, R/RG: arginine and 
glycine rich basic repeats, OR: octa-repeat region, HD: hydrophobic domain, α: α-helical 
region, CHO: N-linked glycosylation acceptor site, S-S: disulfide bridge, GPI-SS: 
glycosylphosphatidylinositol anchor signal sequence. Sequence alignment of the 
hydrophobic domains between PrP and Sho and conserved amino acids are marked in red. 
Biological function of Sho 
The conserved features such as unstructured N-terminal domain, internal 
HD and a C-terminal GPI anchor between PrP and Sho prompted the hypothesis 
that both proteins are functionally related (Premzl et al, 2003). Interestingly, Sho 
can protect cerebellar granule neuronal (CGN) cells from PrP∆HD induced 
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neurotoxicity (Watts et al, 2007). Blocking the expression of Sho in a PrP null 
background leads to a lethal phenotype in mouse embryos suggesting that Sho 
might be required for early embryogenesis (Young et al, 2009). SPRN null allele 
and single nucleotide polymorphisms (SNPs) were identified in CJD patients in the 
UK, supporting a possible role of SPRN genetic variants in prion diseases (Beck et 
al, 2008). The conserved RGG boxes in Sho might be associated with binding of 
RNA molecules (Corley & Gready, 2008). RGG box containing proteins are 
shown to be involved in RNA processing and in some proteins RGG boxes 
mediate the interaction with its binding partners (Lukasiewicz et al, 2007). Similar 
to PrP, localization of GPI-anchored Sho in lipid rafts might indicate a role in 
neural cell signaling. 
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Aim of the study 
As described above, PrPC is ubiquitously expressed and structural 
similarities in PrP between different species suggest that its function might be 
evolutionarily conserved (Calzolai et al, 2005; Wopfner et al, 1999). Despite 
numerous studies, the physiological function of PrP is largely unknown. However, 
different studies in transgenic animals and cultured cells are now supporting the 
idea that PrPC can protect neuronal cells against stress-induced cell death (rev in 
(Westergard et al, 2007). From one class of PrP mutants (PrP∆HD) it emerged that 
PrPC can acquire a neurotoxic potential by deleting the internal HD (Baumann et 
al, 2007; Li et al, 2007b; Shmerling et al, 1998). Interestingly, expression of PrPC 
can completely prevent the neurotoxic activity of PrPΔHD suggesting that PrPC 
and PrPΔHD can induce neurotrophic or neurotoxic signaling via similar signaling 
pathway (Li et al, 2007b; Rambold et al, 2008b). 
A genomic analysis indicated the presence of a PrP-related gene (SPRN) that 
encodes Sho (Premzl et al, 2003). Sho is expressed in the CNS. The sequence 
homology between Sho and PrP is found within the internal HD, however, certain 
features such as, a N-terminal repeat region and a C-terminal GPI anchor are also 
conserved and provoked the hypothesis that Sho and PrP are functionally related 
(Premzl et al, 2003). Moreover similarly to PrP, Sho can rescue neurons from 
PrP∆HD-induced neurotoxicity (Watts et al, 2007). From the above studies, it is 
reasonable to assume that PrP and Sho might transmit their neuroprotective signals 
by activating similar intracellular signaling cascade.  
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Hence, the aim of the present study was: 
• To analyze the biogenesis of human Sho in SH-SY5Y cells, in 
particular; ER import, glycosylation patterns, maturation, dimerization 
and cellular localization. 
• To provide insight into the stress-protective activity of Sho. In 
particular, we aimed to identify domains of Sho that are required for its 
stress-protective activity. To explore the stress-protective activity of Sho 
two different stress paradigms are employed in this study, which 
includes exposition of SH-SY5Y cells to the excitotoxin glutamate and 
the expression of neurotoxic PrP mutant PrP∆HD. 
• To test for the possibility of a conserved function of the N-termini of 
Sho and PrP. 
• To elucidate the role of Sho in PrPSc-induced apoptosis.
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Results 
Sho is highly conserved from fish to mammals and it was predicted to be 
glycosylated and anchored onto the plasma membrane via a GPI moiety (Premzl et 
al, 2003). Although Sho has no overall sequence homology with mammalian PrP, 
some characteristic features are conserved, such as the internal HD, N-linked 
glycosylation and a GPI anchor at the C-terminal. Similar to mammalian PrP, 
zebra fish Sho (zeSho) and mSho were found to be complex glycosylated and 
targeted to the plasma membrane via the GPI anchor (Miesbauer et al, 2006; Watts 
et al, 2007). As an initial step, this study aimed to analyze wild type human Sho 
and the impact of different domains on maturation, trafficking and stress-
protective activity. 
Generation of antibodies against human Sho 
Sho antibodies are not commercially available. Production of antibodies 
against Sho will be useful to detect endogenous Sho level in cells and tissues and 
for further functional characterization of Sho in prion diseases. For the generation 
of the antibodies, the human Sho gene was cloned into the pET-19b vector using 
the restricting enzymes NdeI and XbaI. Further, Sho gene was transformed and 
expressed in E.coli-BL-21 strain. Expression levels of recombinant Sho (rSho) in 
E.coli were high, but the protein was exclusively in the insoluble fraction. For 
immunization, inclusion bodies were purified and solubilized in guanidine 
hydrochloride (GndHCl). With this solution two rabbits were immunized 
(Eurogentec, Belgium). After 90 days, serum samples were collected from the 
immunized rabbits. 
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Figure 10:	   Specificity of anti-human Sho antibody. Human Sho containing a C-
terminal V5 tag was transfected in mouse neuroblastoma (N2a) or SH-SY5Y cell lines 
and the expression was tested by Western blotting using an anti-V5 antibody or the newly 
generated anti-Sho antibody (αSho). 
To examine the activity of anti-Sho antibodies, mouse neuroblastoma (N2a) 
or human neuroblastoma (SH-SY5Y) cell lines were transiently transfected with 
Sho containing a C-terminal V5 tag. After 24 h, cells were washed with cold PBS, 
scraped off the plate, pelleted and lysed in cold detergent buffer and the proteins 
were analyzed by Western blotting using anti-V5 antibodies or serum isolated 
from rabbits immunized with rSho. As shown in figure 10, the newly generated 
polyclonal antibodies against rSho specifically recognized the over expressed 
human Sho. 
Biochemical characterization of mammalian Sho 
Cloning of human Sho and mutants thereof  
Similar to mammalian PrP, human Sho has an N-terminal ER-SS (aa 1-24) 
which mediates ER import. Further, a single glycosylation site is found in the C-
terminal domain (N111) and a glycosylphosphatidylinositol signaling sequence 
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(GPI-SS) at the C-terminus (aa 127-151) (Premzl et al, 2003). zeSho biogenesis 
was previously analyzed in our group. It starts with the translocation of nascent 
Sho polypeptide into the ER lumen, where it undergoes a series of 
posttranslational modifications such as glycosylation and GPI anchor attachment at 
the C-terminal (Miesbauer et al, 2006). Thereafter, the protein is complex 
glycosylated and transported to the outer surface of the plasma membrane 
(Miesbauer et al, 2006).  
 
Figure 11: Schematic presentation of the PrP, Sho and their mutant constructs used 
in this study. ER-SS: endoplasmic reticulum signal sequence, R/RG: arginine and 
glycine rich basic repeats, OR: octa-repeat region, HD: hydrophobic domain, α: α-helical 
region, CHO: N-linked glycosylation acceptor site, S-S: disulfide bridge, GPI-SS: 
glycosylphosphatidylinositol anchor signaling sequence and V5-tag: 
GKPIPNPLLGLDST. 
For biochemical and functional analysis of mammalian Sho, the human 
homologue was synthesized using ligation-based chemical gene synthesis using 
Sloning building block technology (Sloning, Puchheim) (Van den Brulle et al, 
2008) and cloned into a mammalian expression vector pcDNA 3.1/Zeo(+). A V5 
tag (5ʹ′ GGT AAA CCG ATA CCG AAC CCG CTC CTC GGT CTC GAT TCG 
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ACG 3ʹ′) or HA tag (5ʹ′ TAC CCA TAC GAT GTT CCA GAT TAC GCT 3ʹ′) was 
introduced between amino acids 124 and 125. Sho was used as a template to 
generate the subsequent deletions and mutants by standard polymerase chain 
reaction (PCR) method: Sho∆N (aa 30-56 deleted) and Sho∆HD (aa 68-89 
deleted). The design of the Sho mutants was based on PrP mutants that have been 
characterized previously.  
Wild type Sho and Sho mutants are complex glycosylated  
Protein glycosylation maintains the folding, physiological structural and 
cellular localization, thereby enhancing the protein-protein interaction, solubility 
and increases the resistance against proteolysis (Shental-Bechor & Levy, 2008; 
Winklhofer et al, 2003a; Zhou et al, 2005). PrP mutant devoid of unstructured N-
terminal domain (PrP∆N) shows altered neuroprotective activity but still could 
endorse propagation of infectious prions (Fischer et al, 1996; Mitteregger et al, 
2007; Rambold et al, 2008b). Removal of intrinsic HD (aa 113-133 deletion) from 
PrP showed a gain of neurotoxic function which can be repressed by the 
expression of a single copy of PrPC (Baumann et al, 2007; Li et al, 2007a; 
Rambold et al, 2008b; Shmerling et al, 1998). Importantly, these PrP mutants are 
complex glycosylated and are targeted to the outer leaflet of the plasma membrane 
through their GPI anchor (Winklhofer et al, 2003b). 
As previously mentioned, earlier experiments showed that zeSho expressed 
in mammalian cells is complex glycosylated and anchored via a GPI moiety to the 
plasma membrane (Miesbauer et al, 2006). To examine the co and post-
translational modifications of human Sho and the respective mutants indicated in  
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Figure 12: Deletion of the N-terminal or the hydrophobic domain does not interfere 
with biogenesis of Sho. Sho and its mutants are complex glycosylated. SH-SY5Y cells 
were transiently transfected with the constructs indicated in figure 10. Total cell lysates 
were treated with Endo H (A) or PNGase F (B) (+) or left untreated (-) and PrP or Sho 
proteins were detected by Western blotting. 
figure 11 the constructs were expressed in SH-SY5Y cells. To monitor N-linked 
glycosylation, cell lysates were treated with Endoglycosidase H (Endo H), an 
enzyme that cleaves only high mannose structure or Peptide: N-glycosidase F 
(PNGase F), which can remove all N-linked glycans. An increase in the 
electrophoretic mobility of the proteins after PNGase F digestion (Figure 12B) 
indicated that all constructs are modified with N-linked glycans. Endo H treatment 
did not show any difference in the electrophoretic mobility of the proteins (Figure 
12A) indicating that all the constructs are modified with N-linked glycans of 
complex structure. 
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Sho and the mutants are targeted to the outer leaflet of the plasma membrane 
via a GPI anchor 
0.5% of the proteins located at eukaryotic cell membrane are GPI anchored 
(Eisenhaber et al, 2001). Experimental evidence for the cell surface localization of 
Sho was first shown for zeSho (Miesbauer et al, 2006) and later also for mSho 
(Watts et al, 2007). To analyze the cellular localization of the human homologues, 
 
Figure 13: Sho and its mutants are tethered to the outer leaflet of the plasma 
membrane via a GPI anchor. Sho and the different mutants contain a C-terminal GPI 
anchor. Transiently transfected cells were incubated at 4°C for 3 h with PIPLC to release 
GPI-anchored proteins from the cell surface (PIPLC +) or mock-treated (PIPLC -). PrP 
(A) or Sho (B) present in the cell lysates (L) or the cell culture supernatant (M) were 
analyzed by Western blotting. 
Sho and PrP constructs were expressed in SH-SY5Y cells and live cells were 
treated with PIPLC, an enzyme that liberates GPI-anchored proteins from the cell 
membrane. Indeed, PrP and PrP mutants were found in the cell culture medium 
(M) concomitantly with the disappearance of the respective proteins in the cell 
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lysates (L) (Figure 13A). Similarly, levels of Sho and the different mutants were 
diminished in the cell lysates upon treatment with PIPLC. In parallel, Sho and 
Sho∆N levels were increased in the cell culture medium (M) of PIPLC treated 
cells; however, significant amounts of Sho∆HD were not detected in the 
supernatant of PIPLC treated cells, using neither anti-V5 antibody nor newly 
generated rabbit polyclonal anti-Sho antisera (αSho). However, the levels of 
Sho∆HD were significantly decreased in PIPLC treated cells lysates (L) (Figure 
13B). So far, we have not been able to identify the molecular mechanism 
responsible for this peculiar phenomenon.  
 
Figure 14: Sho and the different mutants are present at the outside of the plasma 
membrane. SH-SY5Y cells grown on cover slips were transiently transfected and 
localization of the constructs indicated was analyzed by indirect immunofluorescence of 
non-permeabilized cells. Nuclei were stained with DAPI.  
To provide further evidence for the cellular localization of the Sho 
constructs, an indirect immunofluorescence analysis was performed. Transiently 
transfected SH-SY5Y cells were fixed with 3.7 % paraformaldehyde treatment and 
anti-V5 or anti-PrP antibodies were incubated with the fixed cells. The antibodies 
bind only to the proteins expressed on the cell surface since they cannot penetrate 
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the cell membrane. All constructs including ShoΔHD were detected on the outer 
surface of the plasma membrane (Figure 14). 
Collectively, these findings revealed that full length Sho, as well as its 
mutants, lacking N-terminal or internal HD are complex glycosylated and attached 
to the outer leaflet of the cell membrane through a GPI anchor. 
Sho attenuates glutamate induced excitotoxic stress 
Excessive stimulation of neuronal cells by neurotransmitters such as 
glutamate can damage the neuronal cells through a pathological process called 
excitotoxicity. As previously mentioned, altered LTP and increased neuronal 
excitability have been observed in PrP knockout mice (Collinge et al, 1994; Curtis 
et al, 2003; Maglio et al, 2004; Mallucci et al, 2002). A recent study suggests that 
PrP knockout mice exhibit enhanced NMDAR dependent neuronal excitability 
(Khosravani et al, 2008). These results would indicate that PrPC might be involved 
in attenuating the neuronal excitability by regulating the glutamate receptor’s 
activity. This is the rationale behind the use of glutamate as a physiological stress 
agent to analyze the role of PrP and Sho in stress-induced toxicity. 
SH-SY5Y cells transiently transfected with the constructs indicated in 
figure 11, were grown on cover slips. The cells were treated with 500 µM 
glutamate for 3 h, followed by paraformaldehyde fixation. Apoptotic cells were 
identified by indirect immunofluorescence assay using an antibody against 
activated caspase-3. In this context, it is important to note that SH-SY5Y cells are 
characterized by low levels of endogenous PrPC (Figure 15, right panel, pcDNA, 
3F4). Consistent with previous results, PrPC was able to protect cells against 
excitotoxic cell death whereas the deletion of the intrinsically disordered  
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Figure 15: Sho protects against glutamate stress-induced apoptosis. SH-SY5Y cells 
expressing the constructs indicated were stressed with glutamate (500 µM) for 3 h at 
37°C, fixed, permeabilized and activation of caspase-3 was analyzed by indirect 
immunofluorescence. To detect cells undergoing apoptosis, the number of activated 
caspase-3-positive cells out of at least 1100 transfected cells was determined in at least 
three independent experiments. Percentage of apoptotic cells among transfected cells is 
shown. Expression levels were analyzed by immunoblotting (right panel). *P<0.05, 
**P<0.005, ***<0.0005. 
N-terminal domain (PrP∆N) leads to loss of protective activity (Figure 15) 
(Rambold et al, 2008b). 
Similarly, expression of Sho had a stress-protective ability, which was 
abolished by the deletion of the N-terminal domain (Figure 15). These results 
indicate that the deletion of the N-terminal domain from Sho and PrP has similar 
outcome, i.e, the loss of a stress-protective activity. However, deletion of the 
hydrophobic region (HD) had different consequences. Earlier experiments from 
cell culture and transgenic mice expressing PrP∆HD showed that PrP∆HD 
obtained a toxic activity (Baumann et al, 2007; Li et al, 2007a; Rambold et al, 
2008b; Shmerling et al, 1998). As illustrated in figure 15, PrP∆HD expression was 
toxic to SH-SY5Y cells and also it does not interfere with glutamate induced 
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excitotoxicity. Surprisingly, Sho∆HD expression did not induce apoptotic cell 
death in SH-SY5Y cells, but it was also devoid of a stress-protective activity to 
interfere with glutamate-induced cell death. 
Sho protect cells against PrP∆HD-induced toxicity 
Transgenic mice expressing PrP∆105-125 in a PrP null background exhibit 
neurodegenerative phenotype such as cerebellar atrophy, tremor, granule neuronal 
loss and astrogliosis. This phenotype is eliminated upon expression of full length 
PrP (Li et al, 2007a). Moreover, mSho has been shown to protect neurons from 
PrP∆HD induced neurotoxicity as well (Watts et al, 2007). Therefore, we have 
decided to use the expression of PrP∆HD as a second model for neurotoxic insult 
in order to identify Sho domains required for its activity to protect neurons against 
PrP∆HD induced toxicity. Sho and its mutants were transiently co-transfected with 
PrP∆HD in SH-SY5Y cells. As a control, mock transfection of pcDNA or 
expression of GFP-GPI constructs was used. After 24 h, transfected cells were 
fixed with 3.7% paraformaldehyde solution and stained with anti-active caspase-3 
antibody in order to identify apoptotic cells. PrP mutants corresponding to Sho 
constructs were analyzed in parallel. 
As illustrated earlier, PrP∆HD expression mediated neurotoxicity was 
suppressed by co-expression of full length PrP (Figure 16). Consistent with 
previous results employing cerebellar granule neurons (CGN) (Watts et al, 2007), 
expression of Sho was able to inhibit the toxicity induced by the expression of 
PrP∆HD; whereas control cells (pcDNA and GFP-GPI) do not protect the cells 
from PrP∆HD induced apoptosis (Figure 16). Notably, co-expression of PrP∆N or  
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Figure 16: Expression of Sho interferes with toxic effects of PrPΔHD. SH-SY5Y cells 
were transiently co-transfected with PrPΔHD and the constructs are indicated in the figure 
11. Apoptotic cell death was determined as described under figure 15. Expression levels 
were analyzed by immunoblotting (right panel). To specifically detect PrP∆N cell lysates 
were treated with PNGase F prior to the Western blot analysis (3F4). *P<0.05, 
**P<0.005, ***<0.0005. 
Sho ∆N did not prevent apoptosis in cells expressing PrP∆HD. Similarly, Sho∆HD 
does not interfere with toxic effects of PrP∆HD expression (Figure16).  
The hydrophobic domain mediates homodimerization of Sho 
Oligomerization is frequently linked to the physiological activity of proteins 
and regulation of enzymes and receptors. Dimer formation of GPI-anchored 
proteins cannot only direct their recruitment to the lipid rafts but also promote their 
interaction with their receptors (Cunningham et al, 2003; Simons & Toomre, 
2000). Previous studies have demonstrated that PrP form dimers at the cell surface 
and the HD mediate dimerization of PrPC and are part of the dimer interface 
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(Priola et al, 1995a) (Meyer et al, 2000b; Rambold et al, 2008b). Internal HD of 
Sho shares a high sequence homology to the HD of PrP (44.4%; Figure 9). Thus, it 
is possible that HD of Sho might also exhibit similar dimer forming activity. To 
analyze the dimer forming ability of Sho, ShoS87C (serine at aa 87 replaced with 
cysteine) was cloned in pcDNA 3.1/ Zeo (+) vector using PCR method (Figure 
17). The strategy behind this approach is that when two cysteine residues are close 
together, a stable disulfide bond is formed between them under the physiological 
condition. A similar method was successfully employed to analyze the domains 
involved in dimer forming ability of amyloid precursor protein (APP) (Munter et 
al, 2007) 
 
Figure 17: Schematic presentation of the Sho and PrP cysteine mutants used. For the 
generation of ShoS87C serine at aa 87 replaced with cysteine, whereas for PrPS131C 
generation serine at aa 131 replaced with cysteine. 
To stabilize a potential Sho dimer, serine 87 was replaced by cysteine. If the 
internal HD is involved in Sho homodimerization, newly introduced cysteine 
molecule could form an intermolecular disulfide bond which is stable under non-
reducing conditions. This dimer formation can be observed using Western blot by 
preparing the protein lysates with the sample buffer without reducing agents such 
as 2-mercaptoethanol (ß-ME) or dithiothreitol (DTT). This strategy was 
successfully used before to show dimerization of PrPC (Rambold et al, 2008b). SH-
SY5Y cells were transiently transfected with ShoS87C and in parallel PrPS131C 
was transfected into cells, and was used as control. Cell lysates were prepared in 
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the presence of Laemmli sample buffer with or without ß-ME or DTT and proteins 
were analyzed by Western blotting. Corroborating the earlier results, PrP dimers 
were found in the cell lysates prepared from PrPS131C under non-reducing  
 
Figure 18: The hydrophobic domain is part of the dimer interface. SH-SY5Y cells 
were transiently transfected with PrPS131C or ShoS87C and cell lysates were analyzed 
under reducing (+ βME) or non-reducing (- βME) conditions. Proteins were detected by 
immunoblotting. 
conditions (Figure 18). Similarly, higher molecular weight species appeared with 
the molecular mass similar to Sho dimer indicating the formation of Sho 
homodimer (Figure 18). In the presence of reducing agents the migration pattern of 
ShoS87C was identical to that of wild type Sho, indicating that the introduced 
cysteine residues induced the formation of intermolecular disulfide bond. 
Furthermore, the possible involvement of the N-terminal domain on homo 
dimer formation of Sho was studied. To this end amino acid residues 30-56 were 
deleted from the ShoS87C (ShoΔN,S87C) mutant (Figure 19A). SH-SY5Y cells 
were transiently transfected with ShoΔN,S87C and characterized by Western 
blotting. As shown in figure 19B, ShoΔN,S87C formed dimers similarly to 
ShoS87C. 
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Figure 19: The N-terminal domain is dispensable for dimer formation. Cells 
transiently expressing Sho∆N,S87C were lysed and the protein sample was analyzed by 
Western blotting under either reducing (+βME) or non-reducing condition (-βME). 
To analyze N-linked glycosylation, lysates from ShoS87C and PrPS131C 
expressing cells were incubated with Endo H, or PNGase F. The increased 
electrophoretic mobility of the proteins after PNGase F digestion (Figure 20A; 
lower panel) indicates that cysteine mutants of Sho and PrP were glycosylated. 
Endo H treatment (Figure 20A, upper panel) did not yield any difference in the 
electrophoretic mobility of the proteins revealed that the mutants were complex 
glycosylated. 
To analyze the cellular localization, live SH-SY5Y cells transfected with 
Sho and PrP cysteine mutants were treated with PIPLC. Indeed, both of the 
mutants were found in the cell culture medium after PIPLC treatment (Figure 
20B). This analysis revealed that biogenesis and post-translational modifications of 
ShoS87C and PrPS131C were similar to that of wild type PrP or wild type Sho: 
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ShoS87C and PrPS131C were complex glycosylated, tethered to the outer leaflet 
of the plasma membrane via a GPI anchor. 
 
Figure 20: Cysteine mutants are complex glycosylated attached to the outer leaflet of 
the plasma membrane via a GPI anchor. (A) SH-SY5Y cells expressing the constructs 
indicated were lysed and lysates were treated with Endo H (+), or PNGase F (+), or left 
untreated (-) prior to a Western blot analysis under reducing conditions. (B) Transiently 
transfected cells were incubated at 4°C for 3 h with PIPLC to release GPI-anchored 
proteins from the cell surface (PIPLC +) or mock-treated (PIPLC -). PrP or Sho cysteine 
mutants present in the cell culture supernatant was analyzed by Western blotting under 
non-reducing conditions. 
Sho and PrP homodimers are formed within the cell 
Dimerization has been well described for many membrane and 
transmembrane proteins and can be linked to cell adhesion, migration, proliferation 
and various cellular signaling processes. Sometime dimerization occurs within the 
lumen of ER, for example, some G-protein coupled receptors (GPCRs) are known 
to dimerize within the lumen of ER and then transported to the plasma membrane 
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(Overton & Blumer, 2000; Overton & Blumer, 2002), while other GPCRs dimerize 
at the cell surface upon agonist stimulation (Tateyama et al, 2004). Various 
GPCRs are known to be glycosylated and the functional effects of glycosylation 
differ from one receptor to another receptor (Wheatley & Hawtin, 1999). β1-
adrenergic receptor deglycosylation affects its dimerization and recruitment to the 
plasma membrane (He et al, 2002). Glycosylation was found to be indispensable 
for folding and trafficking of vasoactive intestinal peptide (VIP)-1 receptor, 
thyroid-stimulating hormone (TSH) receptor and follicle stimulating hormone 
(FSH) receptor (Couvineau et al, 1996; Davis et al, 1995; Russo et al, 1991). 
 
Figure 21: Sho and PrP homodimers are formed within the secretory pathway 
independent of N-linked glycosylation. Transiently transfected SH-SY5Y cells were 
grown overnight in the presence of tunicamycin or brefeldin A. Protein extracts were 
prepared and analyzed under reducing (+βME) or non-reducing condition (-βME) by 
immunoblotting. 
We then went on to analyze the role of N-linked glycosylation in the 
homodimer formation of Sho and whether the homodimer formation occurs within 
the cell or at the cell surface. Transiently transfected SH-SY5Y cells expressing 
either PrPS131C or ShoS87C were cultivated overnight in the presence of 
tunicamycin or brefeldin A and dimer formation was analyzed by Western blotting 
as described in the figure 21. Tunicamycin efficiently inhibits the N-linked 
glycosylation proteins and brefeldin A effectively blocks protein transport from 
ER to golgi complex. Homodimers of Sho or PrP could be detected under both 
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conditions (Figure 21) indicating that dimer formation apparently occurs in the 
secretory pathway and is independent of N-linked glycosylation. 
No evidence for the trans dimers at the cell surface 
Trans or cis dimers of proteins are often formed at the cell surface 
depending upon the specific cellular signaling pathways being activated. Cis dimer 
of glial-cell-line-derived neurotrophic factor receptor α1 (GFRα1) was considered 
to interact with glial cell-derived neurotrophic factor (GDNF) molecules (Bespalov 
& Saarma, 2007). This study addresses the possibility that dimer formation occurs 
in trans at the plasma membrane between Sho molecules located on adjacent cells.  
 
Figure 22: No evidence for the formation of Sho trans-dimers. Separately transfected 
cells expressing either ShoS87C-HA or ShoS87C-V5 were mixed and co-cultivated for 
24 h. Cells were lysed and Sho was immunoprecipitated under non-reducing conditions 
with an anti-HA or anti-V5 antibody. The immunopellet was analyzed by Western 
blotting using the anti-HA or anti-V5 antibody. Western blot analysis of the input is 
shown in the right panel. 
For this purpose, a ShoS87C construct with a C-terminal HA instead of the 
V5 tag tag was generated. Separately transfected SH-SY5Y cells expressing either 
ShoS87C-V5 or ShoS87C-HA were mixed and co-cultivated for additional 24 h. 
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The density was chosen to allow cell-cell contact. Cell lysates were prepared and 
incubated with anti-V5 or anti-HA antibodies overnight at 4oC. The protein 
antibody complexes were precipitated using protein A/G agarose beads and 
Western blot was developed using anti-V5 or anti-HA antibodies respectively. As 
shown in figure 22 the co-immunoprecipitation analysis did not indicate the 
formation of trans-dimers. However, we cannot exclude the possibility that Sho 
trans-dimers can form in vivo under certain conditions. 
 
Figure 23: Possible forms of Sho dimers at the cell surface. Schematic diagram 
illustrates Sho homodimer in cis and trans forms. 
Interaction between Sho and PrP 
By various methods, such as co-immunoprecipitation, yeast two 
hybridization systems and cross-linking experiments, various studies have 
described multiple proteins that can interact with PrP at the cell surface or inside 
the cell. As previously mentioned, the HDs of PrP and Sho mediate their 
homodimerization. Thus, it is possible that PrP and Sho might also form PrP/Sho 
heterodimers via the HDs. Such an interaction of Sho with PrP was described in a 
study using yeast two hybridization system and the interaction was mediated 
through the internal HD (Jiayu et al, 2009). 
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This study could suggest that Sho might interact with PrP under 
physiological conditions via its HD. HD induced homodimerization of Sho and 
PrP was illustrated in figure 18. To analyze the possibility of a mixed PrP/Sho 
heterodimer, transiently transfected SH-SY5Y cells expressing both PrPS131C and 
ShoS87C were lysed in ice cold detergent buffer (0.5% Triton X-100, 0.5% sodium 
deoxycholate in PBS) and cell lysates were incubated with the anti-V5 antibody 
overnight at 4oC. Sho immuno complex was precipitated with protein A/G agarose  
 
Figure 24: No evidence for the formation of a mixed PrP/Sho dimer. Transiently 
transfected cells co-expressing PrPS131C and ShoS87C-V5 were lysed and Sho was 
immunoprecipitated under non-reducing conditions using the anti-V5 antibody. The 
immunopellet was then analyzed by Western blotting using the anti-PrP antibody 3F4 or 
the anti-V5 antibody. Sho and PrP present in the lysates prior to the immunoprecipitation 
were analyzed by immunoblotting (right panel, input). 
beads and the immunopellet was then analyzed by Western blotting using a anti-
PrP antibody. Sho homodimers were efficiently detected by developing a control 
Western blot using anti-V5 antibody, however, using this method we were not able 
to show the formation of mixed PrP/Sho dimmers (Figure 24). 
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The N-terminal domain of Sho can restore stress-protective activity of 
PrPΔN 
The functional characterization of Sho mutants presented above revealed a 
critical role of the N-terminal domain for the stress-protective activity of Sho.  
 
Figure 25: The chimeric protein N-Sho/PrP-C (Sho-PrP) was expressed in human 
neuroblastoma cells. (A) Schematic presentation of the chimeric protein Sho-PrP. (B) 
Sho-PrP is efficiently expressed in SH-SY5Y cells. Cell lysate from transiently 
transfected cells were analyzed by Western blotting using 3F4, anti-V5 and αSho 
antibodies. 
Similarly, PrPΔN lacks a stress-protective activity in cell culture and animal 
models (Figure 15 and 16) (Mitteregger et al, 2007; Rambold et al, 2008b). To test 
for the intriguing possibility of a conserved function of the N-terminal domains of 
PrPC and Sho, the N-terminal domain of Sho (aa 1-63) was fused to PrPΔN (aa 89-
251) (Figure 25A). The fusion N-Sho/PrP-C (Sho-PrP) gene was inserted into a 
mammalian expression vector pcDNA3.1/Zeo (+) using the EcoRI and BamHI 
restriction enzymes for further biochemical and functional characterizations. 
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N-Sho/PrP-C is complex glycosylated and GPI-anchored 
To analyze N-linked glycosylation, lysates from Sho-PrP expressing cells 
were incubated with Endo H or PNGase F. The increased electrophoretic mobility 
of the proteins after PNGase F digestion (Figure 26B) indicates that Sho-PrP was 
complex glycosylated, since Endo H treatment (Figure 26A) did not yield any 
difference in the electrophoretic mobility of the proteins. 
 
Figure 26: Post-translational modifications of N-Sho/PrP-C. Cell lysate from 
transiently transfected cells were subjected to the EndoH treatment (A) or incubated with 
PNGase (B) prior to the Western blot analysis. (C) Intact SH-SY5Y cells were treated 
with PIPLC for 3 h, the medium was collected and analyzed by Western blotting using 
the 3F4 antibody. 
To analyze the cellular localization, live SH-SY5Y cells transfected with 
Sho-PrP gene were treated with PIPLC. Indeed, Sho-PrP was found in the cell 
culture medium after PIPLC treatment (Figure 26C). This analysis revealed that 
biogenesis and post-translational modifications of Sho-PrP were similar to that of 
wild type PrP or wild type Sho: the chimera was complex glycosylated and 
tethered to the outer leaflet of the plasma membrane via a GPI anchor. 
Sho-PrP has a stress-protective activity 
Next, the stress-protective activity of Sho-PrP was compared to that of 
PrPΔN. As described earlier, two different toxic conditions were used. 1.Exposure  
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Figure 27: The N-terminal domain of Sho can functionally replace that of PrP. (A) 
Sho-PrP protects against stress-induced apoptosis. SH-SY5Y cells expressing the 
constructs indicated were stressed with glutamate (500 µM) for 3 h at 37°C. Apoptotic 
cell death was determined as described under figure 15. Protein expression levels were 
analyzed by immunoblotting (right panel). Expression of Sho-PrP interferes with toxic 
effects of PrPΔHD. SH-SY5Y cells were transiently transfected with PrPΔHD or PrPΔHD 
and the constructs indicated. Cells undergoing apoptosis were analyzed as described 
under figure 15. Percentage of apoptotic cells among transfected cells is shown. 
Expression levels were analyzed by immunoblotting (right panel). *P<0.05, **P<0.005, 
***<0.0005. 
to the excitotoxin glutamate 2. Expression of the neurotoxic PrP mutant PrPΔHD. 
SH-SY5Y cells were transfected with Sho-PrP and treated with 500 µM glutamate 
or co-transfected with PrP∆HD. The cells were then fixed with 3.7% formaldehyde 
solution and stained with anti-active caspase-3 antibody in order to identify 
apoptotic cells. In contrast to control transfected cells (GFP-GPI), Sho-PrP 
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expressing cells were significantly protected against cell death induced by the 
exposure to glutamate (Figure 27A) or the expression of PrP∆HD (Figure 27B). In 
summary, these experiments revealed that the N-terminal domain of Sho can 
restore the stress-protective capacity of PrPΔN. 
A possible role of Sho in PrPSc-induced toxicity 
Studies in transgenic mice and cultured cells revealed that neuronal 
expression of GPI-anchored PrP is required to mediate prion-induced toxicity 
(Brandner et al, 1996; Chesebro et al, 2005a; Mallucci et al, 2002; Rambold et al, 
2008b). Similar to PrP, Sho also exhibited protective activity against stress-
induced apoptosis in cultured cells (Figure 15 and 16). These findings indicate that 
Sho and PrPC could have overlapping signaling activities and that Sho might also 
to be able to mediate prion-mediated toxicity. 
 
Figure 28: A schematic representation of co-cultivation assay. SH-SY5Y cells grown 
on cover slip were transiently transfected with PrP or Sho constructs. 3 h later the SH-
SY5Y cells were washed and the cover slip was transformed in to a cell culture dish 
containing ScN2a or N2a cells and then co-cultivated for 16-18 h (Adopted from 
Rambold et al, 2008b). 
A novel co-cultivation assay previously established in our group (Rambold 
et al, 2008b) was used to analyze the possible role of Sho in scrapie-induced  
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Figure 29: Sho does not protect against scrapie prions-induced apoptosis. SH-SY5Y 
cells were transiently transfected with the Sho only or PrP constructs as indicated and co-
cultivated with N2a or ScN2a cells. To detect the apoptotic cells fixed cells were stained 
against anti-active caspase-3 antibody and the apoptotic cells were counted as explained 
in figure 15.	  Expression of transfected constructs in the SH-SY5Y cells co-cultivated with 
N2a or ScN2a cells was analysed by immunoblotting using 3F4 or anti-V5 antibodies 
(lower panel). P<0.05, **P<0.005, ***<0.0005. 
cytotoxicity. In this method, the uninfected cells grown on a coverslip were co- 
cultured along with N2a or ScN2a cells. No cell death was observed in SH-SY5Y 
cells expressing low level PrPC, whereas cells overexpressing PrP undergo 
apoptosis in the presence of PrPSc. Interestingly overexpression of PrP-CD4 is not 
able to induce apoptosis. PrP-CD4 is a mutant PrP, a heterologous C-terminal 
transmembrane domain instead of a GPI anchor. This mutant is located at the 
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plasma membrane but not in lipid rafts and has no stress-protective activity 
(Rambold et al, 2008b; Winklhofer et al, 2003c). Since ScN2a cells were reported 
to release PrPSc molecules consistently in the cell culture medium via exosomes 
(Fevrier et al, 2004; Vella et al, 2007), this approach could be a valid tool to 
identify the role of Sho in prion infection. 
SH-SY5Y cells grown on cover slips were transiently transfected with PrP 
and Sho constructs. 4 h later, the transfected cells on cover slips were extensively 
washed with DMEM without FCS and placed in to cell culture dishes either with 
N2a or ScN2a. After 18 h the SH-SY5Y cells were fixed and stained with anti-
active caspase-3 antibody and the apoptotic cells were analyzed as mentioned in 
figure 15. Corroborating previous finding (Rambold et al, 2008b), SH-SY5Y cells 
expressing PrP-CD4 did not undergo apoptosis when co-cultivated with N2a or 
ScN2a cells (Figure 29; PrP-CD4). However, significant increase in apoptotic cell 
death was observed, when SH-SY5Y cells expressing GPI-anchored PrPC were co-
cultivated with ScN2a (Figure 29; PrP). Expression of wild type Sho did not 
decrease viability of SH-SY5Y cells co-cultured with ScN2a cells (Figure 29; 
Sho).  
Further-on, two more questions need to be addressed more elaborately. 
Firstly, can Sho-PrP also transmit a toxic signal similar to PrPC? Expression of 
PrP∆N does not sensitize SH-SY5Y cells to PrPSc-induced cell death (Figure 29; 
PrP∆N). Similarly PrP∆N does not protect the cells against stress-induced cell 
death. But the fusion protein Sho-PrP restores stress-protective signaling. When 
Sho-PrP expressing SH-SY5Y cells were co-cultivated with ScN2a cells, indeed, 
Sho-PrP expression sensitized the SH-SY5Y cells to PrPSc-induced apoptosis 
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indicating that the chimeric protein can efficiently transmit its toxic signals 
identical to PrPC (Figure 29; Sho-PrP). 
Secondly, does Sho protect cells against PrPSc-induced toxicity? Sho has 
been shown to be down regulated in prion infected mice brain (Watts et al, 2007). 
Moreover, the hypothesis from the cell culture experiment is that Sho protected 
neurons from death and the loss of Sho could be implicated in neuronal cell death 
in prion disease. We now have the best cell culture model (Co-cultivation assay) to 
test this hypothesis. However, co-expression of Sho with PrP does not interfere 
with PrPSc-induced apoptosis in SH-SY5Y cells (Figure 29; PrP + Sho). 
Interestingly, a recent study shows that transgenic overexpression of Sho does not 
prolong scrapie disease in mice (Wang et al, 2011). 
PrP∆HD toxic signaling is blocked by NMDA receptor antagonist 
The experiments in transgenic mice and cultured cells showed that the 
expression of PrP∆HD is neurotoxic. Similar to PrPC, PrP∆HD is localized to the 
plasma membrane via GPI moiety and has no direct contact to cytosol. Therefore, 
PrP∆HD requires a transmembrane protein in order to transmit its neurotoxic 
signal. Moreover, wtPrP attenuates PrP∆HD-induced neurotoxicity, glutamate and 
NMDA mediated excitotoxicity. This gives us a clue that PrP and PrP∆HD might 
use the same receptor for their intracellular signaling. Previous results from our 
group indicated that memantine blocks PrPSc-induced toxicity (Resenberger et al, 
2011). Memantine is an antagonist of glutamatergic NMDA receptors. Hence, we 
cautiously wanted to analyze whether memantine has similar effects on PrP∆HD-
induced toxicity. PrP∆HD was expressed in SH-SY5Y cells with or without the  
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Figure 30: Memantine rescues SH-SY5Y cells from PrP∆HD induced apoptosis. SH-
SY5Y cells were transiently transfected with PrP∆HD and cultured overnight in the 
presence of memantine. Apoptotic cells were identified by indirect immunofluorescence 
using the anti-active caspase-3 antibody as explained in figure 15. Protein expression was 
analyzed by immunoblotting using the 3F4 antibody (right panel). * P<0.05, **P<0.005, 
***<0.0005. 
presence of memantine. Indeed, upon the treatment with memantine the apoptotic 
cell death in PrP∆HD expressing cells was significantly reduced (Figure 30).
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Discussion  
The prominent role of PrP in prion diseases is well characterized and so far 
no other molecule has been found to be connected to these diseases. Less than a 
decade ago, in a search for PrP-related proteins using comparative genomics, 
Premzl et al., identified a new PrP-related gene called Shadoo (Sho; Shadow of 
prion protein) (Premzl et al, 2003). Evolutionary origin of PrP and Sho are not 
known. However, a study suggests that the genes of PrP might have co-evolved 
from a common ancestral gene (Premzl et al, 2004). Sho is expressed mainly in 
CNS and is highly conserved from fish to man (Premzl et al, 2003). Although there 
is no overall sequence homology, PrP and Sho have a conserved internal HD and 
both are anchored on the plasma membrane via a GPI moiety. This study provides 
new insights into biogenesis of human Sho and its physiological activity, 
specifically its ability to protect cells against stress-induced apoptosis. 
Biogenesis of human Sho 
Sho is complex glycosylated and attached to the plasma membrane. 
Previously our group analyzed the biogenesis of zeSho in mammalian cells 
and provided the first experimental evidence that Sho is complex glycosylated and 
targeted to the outer leaflet of the plasma membrane (Miesbauer et al, 2006), a 
finding corroborated for mSho later (Watts et al, 2007). In this study, the 
biogenesis of human Sho was analyzed in detail. PNGase F and Endo H, enzymes 
that remove the N-linked glycans from proteins were employed to study the 
glycosylation pattern of Sho. Corroborating previous findings for zeSho and mSho, 
human Sho expressed in SH-SY5Y cells is sensitive to PNGase F but resistant to 
Endo H, indicating that Sho is complex glycosylated. In addition, a possible role of 
N-terminal and HD in Sho biogenesis was also addressed. Similar to wtSho, 
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mutants devoid of N-terminal and HD treated with PNGase F also show difference 
in their migration pattern in comparison with untreated protein samples indicating 
that these mutants are also modified with complex glycans. 
As described above, zeSho and mSho are attached to the plasma membrane 
via GPI moiety. So the next question addressed was whether the human 
homologue is also anchored to the plasma membrane via a GPI moiety. To test 
this, Sho expressing SH-SY5Y cells were treated with PIPLC. As expected, Sho 
was found in the cell culture medium after the PIPLC treatment. Sho mutant 
devoid of the N-terminal domain was also released in to the cell culture medium 
after the PIPLC treatment, whereas, Sho∆HD was undetectable using either anti-
V5 antibody or αSho. But reduced level of Sho∆HD was observed in the cell 
lysates treated with PIPLC. So the expression of Sho∆HD was further analyzed by 
non-permeable fluorescence microscopy technique. Indeed, similar to wtSho, 
expression of Sho∆HD at cell surface was confirmed by fluorescence microscopy. 
Collectively, these results confirm that Sho and its deletion mutants are modified 
with complex glycans, targeted to the plasma membrane through a GPI moiety. 
Moreover, deletion of the N-terminal or the HD does not have any detectable 
impact on Sho biogenesis. 
Sho forms homodimers 
Many GPI anchored proteins have been shown to form dimers. Dimer 
formation is not only linked to the physiological function but also to cellular 
trafficking and targeting to lipid rafts (Mayor & Riezman, 2004; Paladino et al, 
2004; Simons & Toomre, 2000). For example, dimerization was demonstrated for 
CD59, a GPI anchored complement regulatory protein (Hatanaka et al, 1998), 
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GFRα, urokinase-type plasminogen activator receptor (uPAR/CD87) and CD55 
(Airaksinen & Saarma, 2002; Hatanaka et al, 1998). Formation of PrP homodimers 
have been reported previously and that the internal HD is required for dimerization 
and is a part of the dimer interface (Meyer et al, 2000a; Priola et al, 1995b; 
Rambold et al, 2008b). PrP homodimerization was experimentally shown by 
introducing a cysteine residue within the HD of PrP (PrPS131C) (Rambold et al, 
2008b). A similar approach was previously used to analyze the dimerization of 
human epidermal growth factor receptor 2 (Erb-2/Her2) and the amyloid precursor 
protein (APP) (Cao et al, 1992; Munter et al, 2007). Since the HD of Sho is highly 
homologues to the HD of PrP, it is reasonable to assume that Sho might also be 
able to form homodimers via its HD. 
To address this possibility, a modification was introduced into Sho: the 
serine residue at 87th position was replaced by a cysteine residue (ShoS87C). If 
Sho forms a dimer under physiological conditions, the cysteine residues come 
closer and form a disulfide bond. Under non-reducing conditions the dimers can be 
detected by a shift in protein migration on SDS/PAGE. Western blot analysis from 
cultured mammalian cells expressing ShoS87C showed an additional slow 
migrating band in comparison to wtSho under non-reducing conditions.  The 
slower migrating band disappears in the presence of reducing agents such as β-ME 
or DDT indicating that Sho forms homodimers and the homodimer is stabilized by 
an intermolecular disulfide bond via the introduced cysteine residues. PNGase F 
and PIPLC treatment of ShoS87C revealed that the biogenesis is not altered by the 
cysteine modification i.e. similar to wtSho, ShoS87C is also complex glycosylated 
and attached to the plasma membrane through a GPI moiety. 
The next question we addressed was whether the N-terminal domain of Sho 
had an impact on homodimerization. To test this, Sho∆N,S87C (aa 30-56 deleted 
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in ShoS87C) was expressed in cultured mammalian cells and the protein samples 
was analyzed by Western blotting under non-reducing conditions. Indeed, similar 
to ShoS87C, Sho∆N,S87C also forms dimers. These results indicate that the N-
terminal domain is not required for Sho homodimerization. 
Many membrane proteins form dimers within the cell and are transported to 
the outer membrane. For example presence of immature GPCR dimers within the 
ER lumen suggests that dimerization might be an integral part of GPCR maturation 
and an initial step in the production of functional GPCRs (Milligan, 2004). 
Sometimes substrate binding can also induce dimerization of the target proteins at 
the cell surface. For example brain derived neurotrophic factor (BDNF) binding to 
TrkB tyrosine kinase receptor induces receptor dimerization (Blum & Konnerth, 
2005; Scharfman & McNamara, 2010).  
After we obtained experimental evidence for Sho and PrP 
homodimerization, we further wanted to know if Sho and PrP homodimerization 
take place within the cell or at the plasma membrane. To test this, Sho and PrP 
were expressed in mammalian cells in the presence of brefeldin A, a lactone 
antibiotic that blocks the protein transport from ER to golgi. Western blot analysis 
revealed that the Sho and PrP homodimers could be detected after the treatment 
with brefeldin A. This result indicated that Sho and PrP homodimers are formed 
within the secretory pathway. Further, the effect of glycosylation on 
homodimerization was investigated. Mammalian cells expressing ShoS87C and 
PrPS131C were treated with tunicamycin and homodimer formation was analyzed 
by Western blotting. Indeed, Sho and PrP homodimers can be detected under this 
condition. Thus, glycosylation is not required for Sho or PrP homodimer 
formation. 
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Taken together, Sho and PrP homodimer formation occurs within the 
secretory pathway and does not require N-linked glycosylation. Since dimerization 
is a general basic characteristic feature of several membrane receptors, it could be 
possible that homodimerization of Sho and PrP might be linked with cellular 
processes such as maturation, cellular trafficking, binding to their receptors, 
regulation of intracellular signals and endocytosis. 
Signal transduction can be initiated between two different cells through 
protein-protein interaction at the outer surface of the plasma membrane. For 
example, a homodimer of N-Cadherin, a cell adhesion molecule interacts with 
another N-Cadherin homodimer of a neighboring cell to form functional cis-trans 
homotetramer (Kim et al, 2005). Cis homodimers of junctional adhesion molecule 
1 (JAM 1) can bind to other cis homodimer of JAM 1 of the adjacent cell and 
regulate the paracellular permeability and leukocyte transmigration (Kostrewa et 
al, 2001). Thus, the question arose whether Sho can form trans homodimers at the 
cell surface. To address this experimentally, two different tags (V5 and HA tags) 
were introduced into ShoS87C. Cells expressing Sho constructs with two different 
tags were mixed together and grown until the establishment of cell to cell contacts. 
Further, the cells were lysed and the possible formation of a trans homodimer was 
analyzed by co-immunoprecipitation analysis. Using co-immunoprecipitation 
analysis, Sho cis homodimer could be readily detected but not trans homodimers 
or cis-trans homotetramers. However, we cannot rule out the possibility that under 
certain circumstances Sho trans dimers might be formed in vivo in response to a 
specific stimulus.  
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No formation of PrP/Sho mixed dimer 
As described earlier, Sho and PrP contain a highly homologues HD. Since, 
both Sho and PrP can form homodimers via their HD, it is tempting to speculate 
that Sho and PrP may form heterodimers and HD might be a part of the dimer 
interface. Using yeast two-hybrid system, it was demonstrated that Sho can 
interact with PrP, which is mediated by the HD (Jiayu et al, 2009). Further, 
collision induced dissociation (CID) spectral studies suggested that PrP can be co-
purified with Sho or vice versa (Watts et al, 2009). To analyze a possible 
interaction, PrP along with Sho or PrPS131C with ShoS87C were co-transfected, 
protein samples were co-immunoprecipitated and analyzed by Western blotting. If 
Sho and PrP formed a mixed dimer under physiological conditions, introduced 
cysteine molecules might form a disulfide bridge and different migration patterns 
for Sho/PrP heterodimer might be seen on Western blot. However, using this 
approach we were not able to show a PrP/Sho interaction. 
The stress-protective activity of Sho 
Since Sho and PrP share certain structural features, it seems plausible that 
the two proteins have also similar physiological functions. Indeed in 2007, Joel 
Watts and colleagues described a PrP-like neuroprotective activity of Sho. Similar 
to wtPrP, Sho can protect CGN cells against PrP∆HD-induced toxicity (Watts et 
al, 2007). In our study we investigated whether this protective activity of Sho is 
limited to PrP∆HD-induced apoptosis or can also protect cells against other 
physiological stress agents. To test this, glutamate was employed as a model for 
excitotoxic stress. Glutamate is considered to be the main mediator of 
excitotoxicity in the CNS by changing the LTP. Moreover several studies 
suggested that PrP can ameliorate altered LTP and excitotoxicity induced neuronal 
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cell death (Collinge et al, 2004; Khosravani et al, 2008; Rambold et al, 2008b; 
Whittington et al, 1995). 
Mammalian cells expressing PrP or Sho were stressed with acute 
concentration of glutamate and apoptotic cell death was then measured by staining 
cells for active caspase-3. Indeed, similar to PrP, Sho can protect SH-SY5Y cells 
from glutamate stress-induced apoptosis. Further, to map the domains involved in 
this stress-protective activity of Sho, the deletion mutant clones coding for Sho 
protein without the N-terminal or HD were prepared. Stress-protective activity of 
Sho mutants was analyzed by apoptotic cell death as readout. Similar to PrP∆N 
mutant, N-terminally truncated version of Sho lost its stress-protective activity and 
lack of HD also makes Sho functionally inefficient. These results indicate that the 
stress-protective activity of Sho and PrP depend on similar domains i.e, N-terminal 
domain and internal HD. The impaired stress-protective activity of Sho mutants is 
not due to improper cellular trafficking, since both the mutants are complex 
glycosylated and attached to the plasma membrane via a GPI moiety.  
With the above results, it is possible to assume that the N-terminal region 
and the HD are required for the stress-protective function of Sho and PrP. But it is 
still puzzling as to how the N-terminal and HD are involved in stress-protective 
signaling? It has been suggested that the intrinsically disordered domains of 
protein are implicated in protein-protein interaction (Tompa et al, 2009). The N-
terminal domain of PrP is intrinsically disordered and by CD spectroscopic 
analysis of rSho it has been suggested that whole protein might be intrinsically 
disordered (Watts et al, 2007). Therefore, it could be reasonable to assume that the 
N-terminal domain of Sho and PrP may interact with their unidentified co-
receptors involving intracellular signaling cascade. 
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Deleting HD in Sho does not lead to neurotoxic species  
Experiments in transgenic mice revealed the unexpected finding that by 
deleting the intrinsic HD, PrP can gain a neurotoxic potential (Baumann et al, 
2007; Li et al, 2007a; Shmerling et al, 1998). Interestingly, the neurotoxic potential 
of PrP∆HD is independent of replication of infectious prion (rev.in (Winklhofer et 
al, 2008). Co-expression of a single copy of wtPrP can completely abolish the 
neurotoxic phenotype although the cellular mechanism involved in PrP∆HD 
mediated toxicity is unknown (Shmerling et al, 1998). Similar to wtPrP, PrP∆HD 
is also complex glycosylated and targeted to the plasma membrane through a GPI 
anchor (Winklhofer et al, 2003c). An interesting finding is that similar to PrPC, co-
transfection of Sho can counteract PrP∆HD induced toxicity in CGN cells 
indicating that Sho has PrP-like activity in terms of neutralizing the neurotoxicity 
induced by PrP∆HD (Watts et al, 2007).  
As previously mentioned, sequence similarity between Sho and PrP lies 
within the HDs. So the next question addressed was, does the removal of the HD 
from Sho generate neurotoxic species similar to that of PrP∆HD? To test this, 
Sho∆HD expressing mammalian cells were fixed and stained for active caspase-3 
and the apoptosis level was measured. Using a cell culture assay developed in our 
lab, we could reproduce PrP∆HD-induced toxicity. Mammalian cells expressing 
PrP∆HD undergo apoptosis and this phenotype is rescued upon co-expression of 
wtPrP or wtSho. Interestingly, expression of Sho∆HD does not induce apoptosis in 
cultured mammalian cells indicating that removal of the intrinsic HD of Sho does 
not result in toxic species at least under the experimental conditions tested. At the 
same time, mammalian cells undergo apoptosis when Sho∆HD and PrP∆HD are 
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co-expressed indicating that Sho∆HD does not interfere with PrP∆HD-induced 
apoptosis. Although Sho and PrP contain identical HD, acquiring a neurotoxic 
conformer might be exclusive for PrP. 
The N-terminal domain of Sho can functionally replace that of PrP 
Sho and PrP can protect cells against different toxic insults and their 
mutants devoid of N-terminal domain (Sho∆N and PrP∆N) are impaired in their 
stress-protective activity. The next question we addressed was to whether the 
fusion of the N-terminal domain of Sho with PrP∆N can restore its stress-
protective activity. To analyze this, cultured mammalian cells expressing the 
chimeric protein Sho-PrP (N-terminus (aa 1-63) of Sho fused to PrP∆N (aa 89-
251) were stressed with glutamate or co-expressed along with PrP∆HD and 
apoptotic cell death was measured using activated caspase-3 staining. Indeed, 
similar to wtPrP, Sho-PrP protects cultured cells against glutamate or PrP∆HD-
induced apoptosis.  
There is no experimental evidence that either copper or any other metal co-
factors bind to the N-terminal domain of Sho. There is no sequence homology 
between the N-termini of Sho and PrP and the only similarity seems to be that both 
domains are intrinsically disordered. Based on the hypothesis, that the intrinsically 
disordered domains can be involved in protein-protein interaction, it is reasonable 
to assume that N-terminal domain of Sho and PrP bind with same co-receptor to 
mediate stress-protective signaling. 
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Sho does not protect cells from PrPSc-induced apoptosis 
Formation of PrPSc in the CNS of infected individuals is the crucial event in 
prion diseases. Apart from PrP, there is no solid evidence of any other protein to 
play a curtail role in prion disease. After the discovery of Sho, it has been 
hypothesized that it may have an important role in prion disease. Interestingly, it 
was reported that Sho is downregulated in prion infected mice. However, Sho 
mRNA level seems to be unchanged (Lloyd et al, 2009; Watts et al, 2007). 
Identifying the SPRN null allele in two patients affected with vCJD also supports 
the involvement of Sho in prion diseases (Beck et al, 2008). 
To address a possible effect of Sho on PrPSc-induced toxicity, a novel 
method called co-cultivation assay, which is developed in our laboratory, was 
used. PrP and Sho were expressed in cultured mammalian cells and these cells 
were then co-cultivated with ScN2a cells, which are constantly secreting PrPSc in 
the medium. Corroborating previous findings, PrPC expressing cells underwent 
apoptosis in the presence of PrPSc, whereas in contrast, Sho expressing cells were 
not affected by the presence of PrPSc. Further-more, we checked whether co-
expression of Sho with PrP can block PrPSc-induced apoptosis. To test this, Sho 
was co-expressed with PrP and these cells were grown in the presence of PrPSc. 
Co-expression of Sho with PrP failed to protect cells against PrPC dependent PrPSc-
induced apoptosis. A recent study in transgenic mice shows that Sho 
overexpression does not alter scrapie pathogenesis (Wang et al, 2011). Moreover, 
down regulation of Sho in mice infected with different prion strains has been 
studied by Kohtaro Miyazawa and Laura Manuelidis and Sho reduction seems to 
be prion strain specific. For example Sho level seems to be unaffected in mice 
infected with Asian CJD strain whereas Kuru infected mice show a significant 
reduction in Sho level (Miyazawa & Manuelidis, 2010). 
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In summary, our co-cultivation assay results suggest that Sho can neither 
protect cells from PrPSc-induced apoptosis nor can it mediate PrPSc-induced 
toxicity. Together with recently published studies, it appears that Sho cannot 
modulate prion pathogenesis. 
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Summary 
Shadoo (Sho) is the only known protein that has some similarities with the 
cellular prion protein (PrPC). Both proteins are evolutionarily highly conserved 
glycoproteins that are mainly expressed in the brain. Both the proteins share 
common characteristic features such as an unstructured N-terminal domain, a 
homologous internal hydrophobic domain (HD) and a C-terminal 
glycosylphosphatidylinositol (GPI) anchor. Preliminary data also showed that PrP 
and Sho have apparently a similar stress-protective activity. In the present study, 
the biogenesis and physiological function of the human homologue Sho was 
studied. Compared with PrP show here some similarities and differences. 
Similarities 
• Both the proteins are complex-glycosylated and selectively transported by a 
GPI anchor to the outer plasma membrane. Both dimerize within the 
secretory pathway. The dimerization is mediated here by the hydrophobic 
domain. 
• Both have a stress-protective effect, for which the N-terminal domain is 
required. 
• PrP and Sho probably activate similar cellular pathways that protect cells 
from stress-induced apoptosis. 
Differences 
• Unlike PrP∆HD, deletion of the hydrophobic domain of Sho leads to the 
formation of no toxic conformers. 
• Sho does not mediate toxicity induced by PrPSc. 
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Taken together, this study reinforces the view that PrP and Sho could 
mediate their neuroprotective potential by common cellular co-receptors. The 
formation and propagation of toxic conformers is specific for PrP. Although Sho is 
unlikely to contribute to prion pathogenesis, studying the physiological function of 
Sho could be a useful tool to clarify the physiological function of PrP. The 
discovery of the physiological role of PrP is important to understand the 
pathological role of PrP in prion diseases. This knowledge can help to develop new 
therapeutic strategies against prion diseases. 
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Zusammenfassung 
Shadoo (Sho) ist das bisher einzig bekannte Protein, das gewisse 
Ähnlichkeiten mit dem zellulären Prion-Protein (PrPC) aufweist. Beide Proteine 
sind evolutionär hochkonservierte Glycoproteine, die hauptsächlich im Gehirn 
exprimiert werden. Chakterische Merkmale beider Proteine sind eine 
unstrukturierte N-terminale Domäne, eine homologe interne hydrophobe Domäne 
und ein C-terminaler Glycosylphosphatidylinositol (GPI)-Anker. Erste Daten 
zeigten darüber hinaus, dass Sho und PrP offenbar eine ähnliche stress-protektive 
Aktivität besitzen. Im Rahmen der vorliegenden Studie wurde die Biogenese und 
physiologische Funktion des menschlichen Sho-Homologs untersucht. Verglichen 
mit PrP zeigen sich hier einige Ähnlichkeiten und Unterschiede. 
Ähnlichkeiten 
• Beide Proteine werden complex-glykosyliert und gezielt durch einen GPI-
Anker an die äußere Plasmamembran transportiert. Beide dimerisieren 
innerhalb des sekretorischen Signalweges. Die Dimerisierung wird dabei 
durch die hydrophobe Domäne vermittelt. 
• Beide besitzen eine stress-protektive Wirkung, wofür die N-terminale 
Domäne benötigt wird. 
• PrP und Sho aktivieren vermutlich ähnliche zelluläre Signalwege, um 
Zellen vor stress-induzierter Apoptose zu schützen. 
Unterschiede 
• Im Gegensatz zu PrP∆HD führt eine Deletion der hydrophoben Domäne 
von Sho nicht zur Bildung von toxischen Konformeren. 
• Sho vermittelt keine PrPSc-induzierte Toxizität. 
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Zusammengenommen festigt die vorliegende Studie die Ansicht, dass PrP 
und Sho ihr neuroprotektives Potenzial durch gemeinsame zelluläre Co-
Rezeptoren vermittlen könnten. Die Bildung und Propagierung toxischer 
Konformere ist jedoch spezifisch für PrP. Obwhol Sho somit vermutlich nicht zur 
Prion-Pathogenese beiträgt, könnte die Studie der physiologischen Funktion von 
Sho ein nützliches Werkzeug sein, um die physiologische Funktion von PrP zu 
klären. Die Aufdeckung der physiologischen Rolle von PrP ist bedeutend, um die 
pathologische Rolle von PrP in Prion-Erkrankungern zu verstehen. Dieses Wissen 
kann dazu beitragen neue therapeutische Strategien gegen Prion-Erkrankungen zu 
entwicklen.
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Methods 
Molecular biology methods 
Cloning and site directed mutation by polymerase chain reaction (PCR) 
PCR method was employed for the selective amplification of DNA 
fragments using thermostable DNA-polymerase and primers as listed below (see 
primer list) (Saiki et al, 1988). To clone various Sho mutants, the cDNA of wtSho 
in pcDNA 3.1/Zeo (+) was used. To delete the entire domain or to substitute the 
single amino acid of Sho, a two step PCR strategy was used; first DNA fragments 
with oligonucleotides (primers) containing desired mutations with overlapping 
sequence homology were amplified. Further, these amplified fragments are then 
used in a second reaction as template and the hybridizing sequence homologies are 
used as internal primers. By appropriate selection of the internal primers both 
mutations and insertions or deletions are inserted into a gene fragment, while the 
external primers each contain an interface for a restriction endonuclease and 
amplification of the product used.  
Reaction mixer for PCR: 
ddH2O 38.5 µl 
forward primer 10 µM 1 µl 
reverse primer 10 µM 1 µl 
plasmid (1 µg/µl) 1 µl 
Pfu-Buffer 10x with MgSO4 5 µl 
dNTPs 10 mM 2.5 µl 
Pfu-Polymerase (2.5 U/µl) 1 µl 
final volume 50 µl 
  
Table 3. Reaction mixture for PCR program. 
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To amplify the Sho cDNA the following PCR program was used: 
Temperature Time Cycle  
95oC 5 min 1x 
95oC 
50oC 
72oC 
50 sec 
45 sec 
2 min 
30x 
72oC 
10oC 
10 min 
∞ 
1x 
Table 4: PCR program for Sho amplification 
Agarose gel electrophoresis 
To separate linearized DNA fragments from supercoiled DNA or to analyze 
PCR products, 1-2% (w/v) agarose gels in 1x Tris/Borate/EDTA (TBE) buffer and 
0.2 µg/ml ethidium bromide were used depending on the expected size of the 
fragment. A 1 kb size marker was used to define the size of the fragment. 6x 
loading dye was added to the DNA samples and gels were run at 80 V. 
Isolation and purification of DNA fragments from agarose gel 
DNA fragments were cut out of the agarose gel on a UV illuminator and 
purified with the Nucleo Spin Extract kit (Macherey-Nagel) according to the 
manufacturer’s instructions. 
Enzymatic modification of DNA fragments 
Purified DNA fragments were digested with 10 U restriction enzyme and 
the respective reaction buffer according to the manufacturer’s instructions either 
overnight for digestion close to the end of DNA fragments or 1 h at 37°C to digest 
circular DNA. DNA fragments were purified as described above. 
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Alkaline phosphatase treatment 
To avoid self-ligation, the linearized vectors were dephosphorylated with 
shrimp alkaline phosphatase (SAP) before ligation. SAP and SAP reaction buffer 
was added to the digested vector according to the manufacturer’s instructions. The 
mixture was incubated at 37°C for 10 min and heat inactivated at 65°C for 10 min. 
Ligation of cDNA fragments into vector DNA 
To ligate the digested and purified DNA fragment into a respectively 
linearized plasmid, 100-200 ng of the plasmid was mixed with 1-2 µg DNA 
fragment, T4 ligase buffer and T4 ligase in a final volume of 20 µl. The mixture 
was incubated for 3 h at room temperature and heat inactivated for 10 min at 65°C. 
7 µl were used for transformation of competent bacteria of the E. coli strain DH5α  
Preparation of competent bacteria 
A DNA molecule cannot usually pass through the bacterial cell membrane 
since it is a highly hydrophilic molecule. So, the bacterial cells might be competent 
to take up the plasmid DNA into the cells. This is done by making pores and 
destabilizing the cell wall using high concentration of divalent cations. Single 
colony of freshly grown E.Coli DH5α strain was dissolved in 2 ml of Luria broth 
(LB) medium and shaken for 16 h at 37oC. Then the mixture was poured into 250 
ml LB medium and the cells were cultivated for 2-3 h until an OD 590 value of 
0.4-0.6 was reached. Further, the culture was centrifuged at 3750 rpm for 5 min at 
4oC and the bacterial pellet was resuspended in 100 ml of ice cold TFB1 buffer.  
The suspension was incubated on ice for 5 min and then centrifuged at 3750 rpm 
for 5 min at 4oC. The pellet was then resuspended in 10 ml of ice cold TFB2 buffer 
and incubated for 30-60 min on ice. Further, it was aliquoted up to 100 ml and 
competent cells were stored in liquid nitrogen or in -80oC until the use. 
Methods	  
	  
78	  
	  
Transformation of competent bacteria 
The transformation is used for receiving and amplifying the plasmid by 
E.Coli (Sambrook, 1989). 100 ml of competent bacterial cells were gently thawed 
on ice and mixed with ligated or 1 mg of plasmid DNA. After 30 min of 
incubation on ice, the suspension was incubated for 90 seconds at 42oC (heat 
shock) and then kept on ice for 5 min. After adding 400 ml of LB medium without 
antibiotics the culture was shaken for 60-90 min at 37oC and plated in different 
concentrations of antibiotic containing agar plates. Then, the plates were incubated 
at 37oC for 16-20 h. 
Plasmid DNA preparation from bacterial culture 
For the preparation of plasmid DNA Qiagen-Mini/Maxi-Kit was used and 
followed according to the manufacturer’s instructions. 
Sequencing 
The DNA sequencing was performed based on the Sanger’s chain 
termination method (Sanger et al, 1977) by GATC company in Konstanz., 
Germany. 
Cell biology methods 
Cell culture 
Cultivation of cells 
Human neuroblastoma cells (SH-SY5Y) cells were cultured in Dulbecco's 
modified Eagle’s medium (DMEM). The complete medium contained 10% heat 
inactivated fetal calf serum (FCS), 1% antibiotics solution (final concentration was 
1U/ml of penicillin G, 1mg/ml of streptomycin) and 2 mM glutamine. The cell line 
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was cultured as an adherent single monolayer in cell culture flasks at 37oC with 
5% CO2. 
Passaging  
The passaging of the cell line was done on an average every 3-4 days. After 
aspiration of the cell culture medium the cells were rinsed with phosphate buffered 
saline (PBS -/-) and then incubated with trypsin (0.5 g/L) for several minutes. 
Further, the cells were scrutinized carefully, resuspended in prewarmed complete 
medium and divided with the desired seeding ratio into new cell culture flasks. 
Plating the cells 
For plating the cells, the existing quantity of cells was determined using a 
Neubauer cell counting chamber. SH-SY5Y cells were plated at a density of 5 x105 
cells in 3.5 cm culture dishes. For immunofluorescence analysis, cells were thinly 
plated in order to detect individual cells more efficiently. In this case, 4x 105 SH-
SY5Y cells were platted on sterile cover slips in a 3.5 cm cell culture dish. 
Transfection 
The cells were plated 24 h before transfection and then the cells were 
washed with medium without FCS. For transient transfection, the plasmid DNA 
was mixed with Lipofectamine and Plus (Invitrogen) in OptiMEM according to the 
manufacturer’s instructions. After 3 h the transfection mixture was replaced with 
complete medium and the cells were incubated for 24 h at 37oC with 5% CO2 
before proceeding to the experiments as indicated. 
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Harvesting the cells  
Cells were harvested 24 h after the transfection. These cells were washed 
twice with PBS -/- and then scraped off with a cell scraper in PBS -/-. Then, cells 
were centrifuged for 3 min at 3000 rpm and the cells pellet was placed on ice 
before processing for the experiments as indicated. 
Total cell lysate 
The cell pellets were resuspended on ice cold in detergent buffer (0.1% 
Triton X-100 or 0.5% Triton X-100/sodium desoxycholate (DOC) in PBS-/- with 
protease inhibitors and incubated on ice for 10-20 min with harsh vortexing in 
between. The resulting total cell lysate was mixed with Laemmli sample buffer, 
boiled for 10 min at 95oC and analyzed by the SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). 
SDS-PAGE 
The proteins were separated using one-dimensional, discontinues SDS-
PAGE (Laemmli, 1970). The concentration of stacking gel was 4% and for the 
separating gel depending on the size of the protein, an 8-14% polyacrylamide 
concentration was used. Electrophoresis was done at 150-250V in a Hoefer SE600 
chamber. 
Western blot analysis 
For subsequent immunodetection, previously separated proteins by SDS-
PAGE were transferred onto a nitrocellulose membrane (Towbin et al, 1979). The 
protein transfer was performed in transfer buffer at a constant current of 1000 mA 
for 2 h at 4 ° C. 
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Ponceau S staining 
After blotting the membrane was incubated for 5 min in Ponceau S solution 
and rinsed in distilled H2O to check for complete transfer of proteins from the gel 
to the nitrocellulose membrane. Before the immune reaction the membrane was 
decolorized by PBST. 
Immunodetection of proteins 
The immunodetection of proteins was performed using the Enhanced 
Chemiluminescence (ECL) system according to the manufacturer’s instructions. 
First the nitrocellulose membrane was blocked for non-specific binding with 5% 
skimmed milk solution for 1 h at room temperature (RT) and followed by 
incubation with primary antibody or antiserum for 16 h at 4oC. The membrane was 
washed 3 times with PBST for 10 min and incubated with horseradish peroxidase 
(HRP) conjugated secondary anti-mouse or anti-rabbit antibody in PBST for 45-60 
min at room temperature. Subsequently, the membrane was again washed 3 times 
with PBST and incubated with HPR-substrate, and then the blots were exposed to 
the X-ray film to visualize the signals. 
Glycosylation analysis 
For the detection of glycosylation of proteins various methods that were 
employed have been described below. 
Treatment with tunicamycin  
To analyze the protein core glycosylation, tunicamycin which blocks the 
synthesis of all N-linked glycoproteins (N-glycans) was used. Transiently 
transfected cells were incubated with 0.5 mg/ml of tunicamycin at 37oC with 5% 
CO2 and the cell lysates were analyzed by Western blotting. 
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Digestion with Endo H or PNGase F 
To identify whether the N-linked glycosylation of proteins was present in 
the form of a high mannose structure or complex glycosylated, an enzymatic 
digestion of cell lysates with Endo H or PNGase F was performed. Endo H cleaves 
the glycoforms of high mannose structure (Maley et al, 1989; Robbins et al, 1984) 
whereas PNGase F digests the complex glycans (Plummer et al, 1984; Tarentino et 
al, 1985; Tarentino & Plummer, 1987). The cell lysates were mixed with 
denaturing buffer, boiled at 95oC for 10 min and incubated on ice for 5 min. After 
the addition of reaction buffer and the enzyme, the sample was incubated for 1-3 h 
at 37oC and mixed with Laemmli sample buffer. Further-on, the sample was 
resolved on the SDS-PAGE gel and analyzed by Western blotting. 
Treatment with brefedin A 
Transiently transfected SH-SY5Y cells were grown in the presence of 
1µg/ml of brefeldin A, which blocks the protein transport from ER to golgi 
complex and triggers the retrograde protein transport Golgi complex to ER. After 
24 h of transfection the cell lysates were prepared and analyzed by Western 
blotting. 
Indirect immunofluorescence microscopy 
Transiently transfected SH-SY5Y cells were grown on glass cover slips and 
fixed 24 h post transfection with 3.7% PFA for 20 min. Fixed cells were incubated 
with primary antibody for 45 min at 37°C in PBS containing 1% BSA. After 
extensive washing with cold PBS, incubation with the Cy3 conjugated secondary 
antibody followed at 37°C for 30 min. Cells were mounted onto glass slides and 
examined by fluorescence microscopy. 
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Co-immunoprecipitation 
To analyze formation of a mixed PrP/Sho dimer SH-SY5Y cells were co-
transfected with PrPS131C and ShoS87C. At 24 h post-transfection the cells were 
harvested and lysed in ice-cold detergent lysis buffer (0.5% Triton X-100, 0.5% 
sodium deoxycholate in PBS) supplemented with protease inhibitors. Precleared 
lysates were incubated with αV5 antibody overnight at 4°C. The immunocomplex 
was precipitated with protein A sepharose beads and analyzed by Western blotting. 
To analyze formation of Sho trans-dimers, separate dishes of SH-SY5Y cells were 
transfected with either ShoS87C-V5 or ShoS87C-HA. 3 h post-transfection cells 
were extensively washed, trypsinized, mixed together and seeded in one cell 
culture dish. 24 h later, the cells were harvested and analyzed as described above. 
Co-cultivation assay 
SH-SY5Y cells grown on coverslips were transiently transfected with PrP 
and/or Sho constructs using lipofectamine plus reagent. At 3 h after the 
transfection, the cover slips were transferred into cell culture dishes containing 
ScN2a or N2a cells. 16 h later, the apoptotic cell death in transiently transfected 
SH-SY5Y cells was analyzed. 
Apoptosis assay 
As described earlier (Rambold et al, 2006), SH-SY5Y cells were grown on 
cover slips. 24 h after transfection, the cells were incubated with glutamate (500 
µM) for 3 h. The cells were then fixed and activated caspase-3 detected by indirect 
immunofluorescence using an anti-active caspase-3 antibody. To detect cells 
undergoing apoptosis, the number of activated caspase-3 positive cells out of at 
least 1100 transfected cells was determined using a Zeiss Axioscope 2 plus 
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microscope (Carl Zeiss, Göttingen, Germany). Quantifications were based on 
triplicates of at least three independent experiments. 
Statistical analysis 
Data were expressed as means ± SE. All the experiments were performed in 
triplicates and repeated at least three times. Statistical analysis was carried out 
using student’s t-test. P-values are as follows: * P<0.05, **P<0.005, ***<0.0005. 
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Materials 
Biological materials 
Bacterial strain 
DH5α Genotype: supE44, _lac169 (_80lacZ_M15) 
hsdR17, recA1, endA1, gyr96, thi-1, eLA1 
Source: Hanahan, 1983 
Vectors 
 
pcDNA3.1/ZEO(+) 
pET-19b 
Invitrogen, Karlsruhe 
Novagen, Darmstadt 
Cell lines 
SH-SY5Y cells Human neuroblastoma cells (ATCC-Nr. HTB11) 
N2a cells Mouse neuroblastoma cells (ATCC-No. CCL -
131) 
Antibodies 
Anti-PrP 3F4 monoclonal  
Anti-V5 monoclonal 
Anti-HA monoclonal 
Anti-active caspase-3 polyclonal 
Cy3 conjugated anti rabbit 
Cy3 conjugated anti mouse 
Anti-GFP monoclonal 
Anti-Sho polyclonal (αSho) 
Signet Laboratories, Dedham, MA, USA 
Invitrogen, Karlsruhe 
Covance, Münster 
Promega, Mannheim 
Dianova, Hamburg 
Dianova, Hamburg 
Roche Diagnostics, Mannheim 
(Sakthivelu et al, 2011) 
Primer list 
PrP_For HindIII_Forw CCCAAGCTTATGGCGAACCTTGGCTAC 
PrP_Zsho_rev-1 GCCCAGTCCGTAGCCGATCATGGCGCTCCCCAGCAT 
PrP_Zsho_forw-2 ATGCTGGGGAGCGCCATGATCGGCTACGGACTGGGC 
ZSho_Cter_XhoI_rev CGCCTCGACTCAAGCCCACATAATAAC 
ZSho_PrP_For_New-2 TCCCAGAGCAAAGGCTCAGCAGGGGCTGCGGCAGCT 
ZSho_PrP_Rev-1 AGCTGCCGCAGCCCCTGCTGAGCCTTTGCTCTGGGA 
HSho-F-1BamHI CGCGGATCCGCCGCCACCATGAACTGGGCACCCGC 
HSho-PrP-R-2-EcoRI CCGGAATTCTCATCCCACGATCAGGAAGATGAGG 
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HuSho-PrP-New-reve-1 CTGATTATGGGTACCCCCTCCTTGCAGGGAGGAACCCGGGGCACCG 
HuSho-PrP-New-For-2 CGGTGCCCCGGGTTCCTCCCTGCAAGGAGGGGGTACCCATAATCAG 
7-HuSho-∆HD_Rever-1 TCCCCGGGTCCCGCGGCCCTTCTAGCCACGCGCAGGGAGGAACC 
7-HuSho-∆HD_Foew-2 GGTTCCTCCCTGCGCGTGGCTAGAAGGGCCGCGGGACCCGGGGA 
8-HuSho-C87-Rever-1 GGCCCTTCTCCAGCCGCAGCCCGCCGCCAGGCC 
8-HuSho-C87-Forw-2 GGCCTGGCGGCGGGCTGCGGCTGGAGAAGGGGC 
9-HuSho-∆N-Reve-1 GAGGAACCCGGGGCACCGTATCCGCGGCCGCCCTTGGCTG 
9-HuSho∆N-Forw-2 CAGCCAAGGGCGGCCGCGGATACGGTGCCCCGGGTTCCTC 
5-HuSho_NdeI_Forw_ PET GGGAATTCCATATGAACTGGGCACCCGCAACGTGCTGGGCT 
5HuSho_BamHI_Rev_ PET CGCGGATCCCTAGGGCCGCAGCAGCCCCAGGGCT 
3-HuSho_HindII_Forw CCCAAGCTTATGAACTGGGCACCCGCA 
3-HuSho_XbaI_rev CTAGTCTAGACTAGGGCCGCAGCAGCCC 
2-PrP_Cter_Xhol_Rev CCGCTCGAGTCATCCCACGATCAGGAA 
2-ZSho_HindIII_Forw CCCAAGCTTATGCTGGGCAATCAGAAG 
2ZSho-PrP_Rev GCTTCCCTGCCCGGGATATGAGCCTTTGCTCTGGGA 
2-ZSho_PrP_Forw 
TCCCAGAGCAAAGGCTCATATCCCGGGCA
GGGAAGC 
Chemicals and reagents 
Acetone  Merck, Darmstadt 
Agarose Serva, Heidelberg 
Ampicillin Boehringer Mannheim, Mannheim 
Ammonium persulfate (APS)  USB, Clevelan,OH,USA 
Bcto agar Difco Laboratories, Detroit, MI, USA 
Complete Protease-inhibitor  Boehringer Mannheim, Mannheim 
Bromophenol blue Merck, Darmstadt 
Sodium deoxycholate Sigma, Taufkirchen 
Deoxynucleoside triphosphate 
dATP, dCTP, dGTP, dTTP 
Sigma, Taufkirchen 
Ethanol Sigma, Taufkirchen 
EDTA  USB, Clevelan,OH,USA 
Ethidium bromide  Sigma, Taufkirchen 
Acetic acid  Merck, Darmstadt 
Fetal calf serum (FCS) Invitrogen, Karlsruhe 
Disodium hydrogen phosphate Merck, Darmstadt 
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Formamide Merck, Darmstadt 
Gentamicin Sigma, Taufkirchen 
Glutamine Invitrogen, Karlsruhe 
Glutaraldehyde Sigma, Taufkirchen 
Glycerol  USB, Cleveland, OH, USA 
Glycine USB, Cleveland, OH, USA 
Urea Sigma, Taufkirchen 
Yeast extract Difco Laboratories, Detroit, MI, USA 
Immersion oil Merck, Darmstadt 
Instant-­‐skimmed milk powder  Uelzena, Uelzen 
Potassium acetate Sigma, Taufkirchen 
Potassium chloride USB, Cleveland, OH, USA 
Potassium dihydrogen phosphate  Merck, Darmstadt 
Copper sulfate Sigma, Taufkirchen 
L-[35S]-Methionine  AmershamPharmacia Biotech,Freiburg 
Lipofectamine reagent  Invitrogen, Karlsruhe 
Magnesium chloride USB, Cleveland, OH, USA 
Manganese chloride Sigma, Taufkirchen 
Methanol  Merck, Darmstadt 
Sodium chloride Merck, Darmstadt 
Sodium nitrate Merck, Darmstadt 
Diatrizoate sodium Sigma, Taufkirchen 
PBS Dulbecco’s -/- Mg/Ca  Invitrogen, Karlsruhe 
PBS Dulbecco’s +/+ Mg/Ca  Invitrogen, Karlsruhe 
Penicillin Invitrogen, Karlsruhe 
Plus reagent  Invitrogen, Karlsruhe 
Polyacrylamide/Bisacrylamide (29:1) 
40%  
Roth, Karlsruhe 
Ponceau S  Sigma, Taufkirchen 
ProMix 35S-Methionine/Cysteine  AmershamPharmaciaBiotech, Freiburg 
Protease-inhibitor mix Sigma, Taufkirchen 
Protein A-agarose  Pierce,Perbio Science, Bonn 
Protein A-trisacryl- matrix Pierce, Perbio Science, Bonn 
Protein G-matrix  Pierce, Perbio Science, Bonn 
Proteasome inhibitor MG132 Calbiochem, Bad Soden 
RediPrimeTM II DNA labeling system  AmershamPharmacia Biotech, Freiburg 
Rubidium chloride Sigma, Taufkirchen 
Hydrochloric acid Merck, Darmstadt 
Sarkosyl  USB, Cleveland, OH, USA 
SDS  Roth, Karlsruhe 
Streptomycin  Invitrogen, Karlsruhe 
TEMED  USB, Cleveland, OH, USA 
Trichloroacetic acid Sigma, Taufkirchen 
Tris  USB, Cleveland, OH, USA 
Triton X-100 USB, Cleveland, OH, USA 
Trypan blue Invitrogen, Karlsruhe 
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Tunicamycin  Sigma, Taufkirchen 
Tween-20  USB, Cleveland, OH, USA 
β-Mercaptoethanol  Merck, Darmstadt 
Medium 
Dulbecco's Modified Eagle's medium 
(DMEM), 
Invitrogen, Karlsruhe 
Minimal Essential Medium (MEM), Invitrogen, Karlsruhe 
Minimal Essential Medium, without L-
Methionine 
Invitrogen, Karlsruhe 
OPTIMEM Invitrogen, Karlsruhe 
LB-Medium 1% NaCl 
1% Bacto tryptone 
0.5% Yeast extract 
100 mg / ml Ampicillin and 30 mg / ml 
Kanamycin ( added after autoclaving) 
LB-Agar LB medium + 1.5% Bacto agar 
100 µg/ ml Ampicillin and 30 mg / ml 
Kanamycin (added after autoclaving) 
Kits 
ECL RPN 2106 Amersham Pharmacia Biotech, Freiburg 
Immobilon Western chemiluminescent 
HRP substrate 
Millipore, Schwalb Bach 
Protein assay kit Bio-Rad, München 
QIAprep spin plasmid extraction kit 
Mini / Maxi  
Qiagen, Hilden 
QIAquick gel extraction kit Qiagen, Hilden 
TNT T7 quick coupled transcription / 
translation system 
Promega, Mannheim 
Equipments 
Agarose gel electrophoresis  Central workshop, MPI, Martinsried 
Mettler Toledo AG285 Analytical 
Balance  
Mettler-Toledo GmbH, Giessen 
Incubators  Heraeus, Hanau 
X-Omat Kodak film developer, Stuttgart  
X-Omat Film developer  Kodak, Stuttgart 
Gel documentation system MWG Biotech, Ebersberg 
Gel dryer SGD300  Savant, Holbrook, NY, USA 
GS-6R refrigerated centrifuge with rotor 
GH3.8 
Beckmann, Unterschleissheim 
J2-21M refrigerated centrifuge with 
rotor JA-14 
Beckmann, Unterschleissheim 
Microscope Axiovert 25, 200M Carl Zeiss, Göttingen 
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Axioscope2 plus microscope 
(Axiovision software)  
Carl Zeiss, Göttingen 
pH meter  Fisher Scientific, Nidderau 
Pipettes (P10, P20, P100, P200)  Abimed Gilson, Langenfeld 
Pipette (P1000)  Eppendorf, Hamburg 
Polyacrylamide gel electrophoresis  Amersham Biosciences, Freiburg 
PCR machine T3 thermocycler Biometra GmbH, Göttingen 
Thermomixer Eppendorf, Hamburg 
Table centrifuge centrifuge 5415C  Eppendorf, Hamburg 
Solutions and buffers 
APS solution  10% APS in PBS 
Blocking milk for Western blot  5% Skimmed milk powder in 1x PBST 
Blocking buffer for IF  1% BSA in PBS 
Coomassie destaining solution 40% Methanol 
7% Acetic acid 
DNA sample buffer (6x) 0.25% Bromophenol blue 
30% Glycerol 
Laemmli sample buffer (2x) 
 
 
120 mM Tris pH 6.8 
2% SDS 
20% Glycerol 
0.5% Bromophenol blue 
2% β-Mercaptoethanol 
Lysis buffer 
 
 
0.5% Triton X-100, 0.5% DOC + 
Protease inhibitor in PBS 
PCR mix 
 
1200 µl of H2O 
200 µl of 10x Pfu / Taq buffer 
each 2 µl of dNTPs 
PBS (cell culture) Gibco, BRL Life Technologies, 
Karlsruhe 
PBS (10x) 
 
80 g of NaCl 
2 g of KCl 
14.4 g of Na2HPO4 x 2 H2O 
2.4 g of KH2PO4 
for 1000 ml of H2O 
PBS-T (1x)  1% Tween-20 in 1x PBS 
Pfu polymerase buffer (10x)  Promega, Mannheim 
Ponceau S staning solution 
 
0.2 g of Ponceau S 
5 ml of acetic acid 
100 ml of H2O 
Stacking gel buffer for SDS-PAGE 
 
0.5 M Tris, pH 6.8 
0.4% SDS 
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pH 6.8 
Separating gel buffer for SDS-PAGE 
 
1.5 M Tris, pH 8.8 
0.4% SDS 
pH 8.8 
Shrimp alkaline phosphatase buffer 
(10x)  
Roche Diagnostics, Mannheim 
T4 DNA ligase buffer (10x)  MBI Fermentas, St. Leon-Rot 
TAE buffer (50x) 
 
2 M Tris base 
57.1 ml of Glacial acetic acid 
50 mM Na2EDTA x 2H2O, pH 8.0 
add1000 ml of H2O 
TE buffer 
 
10 mM Tris-HCl, pH 7.5 
1 mM EDTA, pH 8.0 
Western blot transfer buffer 
 
20 mM Tris-Base 
150 mM Glycine 
0.01% SDS 
20% Methanol 
Tunicamycin  10 mg/ml in H2O 
Brefeldin A 5mg/ml in Ethanol 
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Abbreviations 
APS Ammonium persulfate 
aa Amino acids 
ATP Adenosine triphosphate 
BAX Bcl-associated X protein 
Bcl-2 B-cell lymphoma 2 
BiP  Immunoglobulin heavy chain binding protein 
bp  Base pairs 
BSA  Bovine serum albumin 
BSE  Bovine spongiform encephalopathy 
oC Celsius 
CHO N-linked glycosylation 
CJD Creutzfeldt-Jakob disease 
CNS Central nervous system 
CWD Chronic wasting disease 
Da  Dalton 
DAPI  4',6-diamidino-2 phenylindoldihydrochlorid 
dATP  Deoxyadenosine triphosphate 
dCTP  Deoxycytosine triphosphate 
dGTP  Deoxyguanosine triphosphate 
dNTP  Deoxynucleotide triphosphates 
DMEM  Dulbecco's Modified Eagle's Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DOC Deoxycholate 
DRM Detergent-resistant membranes 
DTT  Dithiothreitol 
ECL Enhances chemiluminescence 
E.coli  Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 
Endo H Endoglycosidase H (Endo-β-N-acetylglucosaminidase H) 
ER  Endoplasmic reticulum 
FCS  Fetal calf serum 
FFI  Fatal familial insomnia 
FSE  Feline spongiform encephalopathy 
g Standard gravity 
GPI  Glycosyl-inositol-Phophatidyl 
GSS  Gerstmann-Sträussler-Scheinker syndrome 
h Hour 
HD  Hydrophobic domain 
HRP,  Horseradish peroxidase 
Hsp  Heat shock protein 
IF  Immunofluorescence 
IP  Immunoprecipitation 
kb  Kilo base pairs 
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kDa  Kilodaltons 
S-S Disulfide bond 
M Molar  
MEM  Minimum essential medium 
ml Milliliter 
mm Millimolar 
Min Minutes 
Mg Milligram 
MG132 N-(benzyloxycarbonyl) leucinylleucinylleucinal 
NMDAR N-Methyl-D-Aspartate receptor 
NMR Nuclear magnetic resonance spectroscopy 
OR Octa repeat 
ORF Open reading frame 
PAGE  Polyacrylamide gel electrophoresis 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PIPLC Phosphatidylinositol-specific phospholipase C 
PK  Proteinase K 
PNGase F   Peptide: N-glycosidase F 
PrP  Prion protein 
PrPC    Cellular prion protein 
PrPSc Scrapie prion protein 
pH Negative logarithm of the H3O+- ion concentration 
Ponceau S 3-hydroxy-4-[2-sulfo-4-(4-sulfonatophenylazo)-phenylazo] - 
2.7 naphthalene disulfonic acid 
SAP  Shrimp alkaline phosphatase 
SDS  Sodium dodecyl sulfate 
Sho Shadoo 
SOD  Superoxide dismutase 
TEMED  N, N, N ', N'-tetramethylethylenediamine 
TCA  Trichloroacetic acid 
TE  Tris-EDTA 
Tris Tris(hydroxymethyl)aminomethane 
Triton X-100 t-octylphenoxypolyethoxyethanol 
TSE Transmissible spongiform encephalopathies 
Tween 20 Polyoxyethylen-Sorbitan-Monolaurate 
U Enzyme activity, reaction of 1 mmol substance / min 
V Volt 
wt Wild type 
 
	  117	  
	  
Curriculum vitae 
Personal Details  
Name Vignesh Sakthivelu 
Date of Birth  07th July 1981 in Coimbatore, India 
Father’s Name Mr. Sakthivelu Lingae Gowda 
Mother’s Name Mrs. Santhi Sakthivelu 
Address  Gmunderstr 7, 81379 München 
Marital Status Single  
Nationality  Indian 
Education 	  
Oct 2007 - present Laboratory for Neurodegenerative Disease Research, 
Neurobiochemistry, Ludwig-Maximilians-University 
Munich, Germany  
PhD project: “Functional characterization of Shadoo, a 
PrP-like protein with neuroprotective activity”. 
Supervisor: Prof. Dr. Jörg Tatzelt, Ph.D.  
Sep 2003 – Feb 2007 Bioorganic and Neurochemistry Lab, Central Leather 
Research Institute, Chennai, Tamil Nadu, India. 
Research Scholar. 
Project title: “The neuroprotective efficacy of alpha-
crystallin against acute inflammation in mice”. 
Supervisor: Dr.R.Jayakumar, Ph.D. 
Jun 2001- Apr 2003 M.Sc., (Master of Science) in Biotechnology, Periyar 
University, Salem, Tamil Nadu, India. 
Jun 1998- Apr 2001 B.Sc., (Bachelor of Science) in Biochemistry, 
Bharathiyar University, Coimbatore, Tamil Nadu, 
India. 
Jun 1997- Apr 1998 HSC (Higher Secondary Course), MSSD Higher 
Secondary School, Coimbatore, Tamil Nadu, India. 
Jun 1995- Apr 1996 SSLC (Secondary School Leaving Certificate), SFV 
Govt. High School, Coimbatore, Tamil Nadu, India 
	  118	  
	  
Publications   
Sakthivelu V, Seidel RP, Winklhofer KF, Tatzelt J (2011) Conserved stress-
protective activity between prion protein and shadoo. J Biol Chem 286: 8901-8908.  
 
Gunasingh MJ, Philip JE, Ashok BS, Kirubagaran R, Jebaraj WC, Davis GD, Vignesh 
S, Dhandayuthapani S, Jayakumar R (2008) Melatonin prevents amyloid protofibrillar 
induced oxidative imbalance and biogenic amine catabolism. Life Sci 83: 96-102. 
 
Jesudason EP, Masilamoni JG, Ashok BS, Baben B, Arul V, Jesudoss KS, Jebaraj 
WC, Dhandayuthapani S, Vignesh S, Jayakumar R (2008) Inhibitory effects of short-
term administration of DL-alpha-lipoic acid on oxidative vulnerability induced by 
Abeta amyloid fibrils (25-35) in mice. Mol Cell Biochem 311: 145-156. 
 
Masilamoni JG, Jesudason EP, Dhandayuthapani S, Ashok BS, Vignesh S, Jebaraj 
WC, Paul SF, Jayakumar R (2008) The neuroprotective role of melatonin against 
amyloid beta peptide injected mice. Free Radic Res 42: 661-673. 
 
Masilamoni JG, Vignesh S, Kirubagaran R, Jesudason EP, Jayakumar R (2005) The 
neuroprotective efficacy of alpha-crystallin against acute inflammation in mice. Brain 
Res Bull 67: 235-241. 
 
Conferences and workshops attended 
Graduate Retreat Neurodegenerative Disease Research  
Fraueninsel, Chiemsee, Germany, Oct. 28-30 2007. 
Talk: Characterization of the physiological function of mammalian prion protein 
 
Ringberg Symposium: Molecular Mechanisms of Prion diseases and Parkinson’s 
disease  
Ringberg Castle, Rottach-Egern, Germany, March 5-8 2008 
 
Prion 2009- Transmissible Spongiform Encephalopathies 
Porto Carras Grand Resort, Chalkidiki, Greece, 23-25 September 2009 
 
Workshop: Young Researchers Event: Training in scientific communication. 
Organized by Neuroprion in NIKITI - ELIA BEACH, Greece, 19-22 September 2009 
Stipends 
PhD fellowship awarded by DAAD (German Academic Exchange Service, Germany) 
from Jun-2007- Mar 2011. 
Travel grant awarded to attend the Neuroprion Young Researchers Training Event in 
Greece from 19-22 Sep 2009. 
 
